View source for Pfizer

{{Short description|American multinational pharmaceutical and biotechnology corporation}}
{{About||other uses}}
{{Use American English|date=November 2015}}
{{Use mdy dates|date= November 2015}}
{{Infobox company
| name = Pfizer Inc.
| logo = Pfizer (2021).svg
| logo_size = 250px
| logo_caption = Logo used since 2021
| type = [[Public company|Public]]
| traded_as = {{ubl|{{New York Stock Exchange|PFE}}|[[S&P 100]] component|[[S&P 500]] component}}
| founders = {{ubl|[[Charles Pfizer]]|[[Charles F. Erhart]]}}
| founded = {{start date and age|1849}} in [[New York City]]
| industry = {{Unbulleted list|[[Pharmaceutical industry|Pharmaceutical]]|[[Biotechnology]]}}
| hq_location = [[The Spiral (New York City)|The Spiral]]
| hq_location_city = New York City
| hq_location_country = US
| area_served = Worldwide
| key_people = [[Albert Bourla]]<br />(chairman and CEO)
| products = {{hlist|[[Medication|Pharmaceutical drugs]]|[[vaccine]]s}}
| revenue = {{increase}} {{US$|63.6{{nbsp}}billion}}
| revenue_year = 2024
| operating_income = {{increase}} US$10.6{{nbsp}}billion
| income_year = 2024
| net_income = {{increase}} US$8.02{{nbsp}}billion
| net_income_year = 2024
| assets = {{ decrease }} US$219.4{{nbsp}}billion
| assets_year = 2024
| equity = {{ increase }} US$176.2{{nbsp}}billion
| equity_year = 2024
| num_employees = {{circa|88,000}}
| num_employees_year = 2024
| website = {{Official URL}}
| footnotes = <ref name=2024-10K>{{cite web |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/78003/000007800325000054/pfe-20241231.htm |title=Pfizer Inc. 2024 Form 10-K Annual Report |publisher=[[U.S. Securities and Exchange Commission]] |date=February 27, 2025}}</ref>
}}
{{multiple image
| width = 140
| image1 = Pfizer logo.svg
| caption1 =
| image2 = Pfizer.svg
| caption2 =
| footer = Former corporate logos (until 2021).
}}

[[File:Shinjuku Bunka Quint Building.jpg|thumb|130px|The headquarters of Pfizer in Tokyo, Japan]]

'''Pfizer Inc.''' ({{IPAc-en|ˈ|f|aɪ|z|ər}} {{Respell|FY|zər}})<ref>{{Citation |last=Wells |first=John C. |title=Longman Pronunciation Dictionary |year=2008 |edition=3rd |publisher=[[Longman]] |isbn=978-1-4058-8118-0}}</ref> is an American [[Multinational corporation|multinational]] [[Pharmaceutical industry|pharmaceutical]] and [[biotechnology]] corporation headquartered at [[The Spiral (New York City)|The Spiral]] in [[Manhattan]], New York City. Founded in 1849 in New York by German entrepreneurs [[Charles Pfizer]] (1824–1906) and [[Charles F. Erhart]] (1821–1891), Pfizer is one of the oldest pharmaceutical companies in [[North America]].

Pfizer develops and produces [[medication]] and [[vaccine]]s for [[immunology]], [[oncology]], [[cardiology]], [[endocrinology]], and [[neurology]]. The company's largest products by sales are Eliquis ([[apixaban]]) ($7.3 billion in 2024 revenues, 11% of total revenues), Prevnar (a [[pneumococcal conjugate vaccine]]) ($6.4 billion in 2024 revenues, 10% of total revenues), Paxlovid ([[Nirmatrelvir/ritonavir]]) ($5.7 billion in 2024 revenues, 9% of total revenues), Vyndaqel ([[tafamidis]]) ($5.4 billion in 2024 revenues, 8% of total revenues), Comirnaty (the [[Pfizer–BioNTech COVID-19 vaccine]]) ($5.3 billion in 2024 revenues, 8% of total revenues), and Ibrance ([[palbociclib]]) ($4.3 billion in 2024 revenues, 6% of total revenues).<ref name=10K/> In 2024, 61% of the company's revenues came from the United States, 4% came from China, and 35% came from other countries.<ref name=10K>{{cite web |url=https://www.sec.gov/ix?doc=/Archives/edgar/data/78003/000007800324000039/pfe-20231231.htm |title=Pfizer Inc. 2023 Form 10-K Annual Report |publisher=[[U.S. Securities and Exchange Commission]] |date=February 22, 2024}}</ref>

The company is ranked fifth on the [[list of largest biomedical companies by revenue]]. It is ranked the 69th on the [[Fortune 500|''Fortune'' 500]]<ref>{{cite web |title=Fortune 500: Pfizer |url=https://fortune.com/company/pfizer/fortune500/ |publisher=[[Fortune (magazine)|Fortune]]}}</ref> and 73rd on the [[Forbes Global 2000|''Forbes'' Global 2000]].<ref>{{cite web | title=Forbes: Ecolab | url=https://www.forbes.com/companies/pfizer/ | publisher=[[Forbes]]}}</ref>

==History==
[[File:Charlespfizer.jpg|right|thumb|upright|Charles Pfizer (1824–1906)]]

=== 1849–1950: Early history ===
Pfizer was founded in 1849 as "Charles Pfizer & Company" by [[Charles Pfizer]] and [[Charles F. Erhart]],<ref>{{Cite book |url=http://archive.org/details/internationaldir0178unse |title=International Directory of Company Histories |date=2016 |publisher=St. James Press |isbn=978-1-4103-9198-8 |volume=178 |pages=362–373 |chapter=Pfizer Inc.}}</ref> two cousins who had immigrated to the United States from [[Ludwigsburg]], Germany. The business produced chemical compounds, and was headquartered on Bartlett Street<ref name="Citycyclopedia">Kenneth T. Jackson. ''The Encyclopedia of New York City''. The New York Historical Society; Yale University Press; September 1995. P. 895. {{ISBN|978-0-300-05536-8}}</ref> in [[Williamsburg, Brooklyn]], where they produced an [[antiparasitic]] called [[santonin]]. This was an immediate success, although it was production of [[citric acid]] that led to Pfizer's growth in the 1880s. Pfizer continued to buy property in the area (by now the Williamsburg district of the city of [[Brooklyn, New York]] and beginning in 1898, the [[City of Greater New York]]) to expand its lab and factory, retaining offices on Flushing Avenue until the 1960s; the Brooklyn plant ultimately closed in 2009.<ref>{{Cite news |url=https://www.nytimes.com/2007/01/28/nyregion/28pfizer.html |title=Pfizer's Birthplace, Soon Without Pfizer |work=[[The New York Times]] |date=January 28, 2007}}</ref> Following their success with citric acid, Pfizer (at the now-demolished 295 Washington Avenue) and Erhart (at 280 Washington Avenue) established their main residences in the nearby [[Clinton Hill, Brooklyn|Clinton Hill]] district, known for its concentration of [[Gilded Age]] wealth.{{cn|date=November 2024}}

In 1881, Pfizer moved its administrative headquarters to 81 Maiden Lane in [[Manhattan]], presaging the company's expansion to [[Chicago]], Illinois, a year later.<ref name="Citycyclopedia" /><ref name=collection/> By 1906 sales exceeded $3{{nbsp}}million.<ref name=history>{{Cite web |title=Company Timeline: a Legacy of Innovation |url=https://www.pfizer.com/about/history |url-status=live |website=Pfizer |archive-url=https://web.archive.org/web/20220408162711/https://www.pfizer.com/about/history |archive-date=2022-04-08 |access-date=2022-05-16}}</ref>

[[World War I]] caused a shortage of [[calcium citrate]]. Pfizer imported the compound from Italy for the manufacture of citric acid, and due to the disruption in supply, the company began a search for an alternative.<ref name=":5">{{Cite book |last=Malhotra |first=Girish K. |title=Active Pharmaceutical Ingredient Manufacturing: Nondestructive Creation |publisher=Walter de Gruyter GmbH & Co KG |year=2022 |isbn=978-3-11-070284-2 |page=7 }}</ref> They found this in the form of a [[fungus]] capable of fermenting sugar to citric acid. By 1919, the company was able to commercialize production of citric acid from this source.<ref name=":5" /> The company developed expertise in fermentation technology as a result. These skills were applied to the [[History of penicillin#Deep submergence for industrial production|deep-submergence mass production]] of [[penicillin]], an [[antibiotic]], during [[World War II]] in response to the need to treat injured Allied soldiers.<ref name=Fermentation>{{Cite web |title=Penicillin Production through Deep-tank Fermentation – National Historic Chemical Landmark |url=https://www.acs.org/content/acs/en/education/whatischemistry/landmarks/penicillin.html |publisher=[[American Chemical Society]]}}</ref> The company also embarked on a global [[soil]] collection program related to improving production yields of penicillin which ultimately resulted in 135,000 samples.<ref>{{Cite book |last=Johnson |first=Steven |author-link=Steven Johnson (author) |title=Extra Life |publisher=[[Riverhead Books]] |year=2021 |isbn=978-0-525-53885-1 |edition=1st |page=160 }}</ref>

On June 2, 1942, the company incorporated under the [[Delaware General Corporation Law]].<ref name=10K/>

=== 1950–1980: Pivot to pharmaceutical research and global expansion ===
Due to price declines for [[penicillin]], Pfizer searched for new antibiotics with greater profit potential. Pfizer discovered [[oxytetracycline]] in 1950, and this changed the company from a manufacturer of [[fine chemical]]s to a research-based pharmaceutical company. Pfizer developed a [[drug discovery]] program focused on in vitro synthesis to augment its research in fermentation technology. In 1959, the company established an [[animal health]] division with a {{cvt|700|acre|km2|adj=on}} farm and research facility in [[Terre Haute, Indiana]].<ref name=Fermentation/>

By the 1950s, Pfizer had established offices in Belgium, Brazil, Canada, Cuba, Mexico, Panama, Puerto Rico, and the United Kingdom. In 1960, the company moved its medical research laboratory operations out of New York City to a new facility in Groton, Connecticut. In 1980, Pfizer launched Feldene ([[piroxicam]]), a prescription anti-inflammatory medication that became Pfizer's first product to reach $1{{nbsp}}billion in revenue.<ref name=history/>

In 1965, John Powers, Jr. became [[chief executive officer]] of the company, succeeding John McKeen.<ref name=history/>

As the area surrounding its Brooklyn, NY plant fell into decline in the 1970s and 1980s, the company formed a public-private partnership with New York City that encompassed the construction of low- and middle-income housing, the refurbishment of apartment buildings for the homeless and the establishment of a [[charter school]].<ref name=collection>{{Cite web |url=http://dlib.nyu.edu/findingaids/html/bhs/arc_084_pfizer/bioghist.html |title=Guide to the Pfizer Inc. collection ARC.084 |publisher=[[Brooklyn Public Library]]}}</ref>

In 1972, [[Edmund T. Pratt Jr.]] became [[chief executive officer]] of the company, succeeding John Powers, Jr.<ref name=history/>

=== 1980–2000: Development of Viagra, Zoloft, and Lipitor ===
In 1981, the company received approval for Diflucan ([[fluconazole]]), the first oral treatment for severe [[fungal infection]]s including [[candidiasis]], [[blastomycosis]], [[coccidiodomycosis]], [[cryptococcosis]], [[histoplasmosis]], [[dermatophytosis]], and [[pityriasis versicolor]].<ref>{{cite web |title=Fluconazole |url=https://www.drugs.com/monograph/fluconazole.html |publisher=The American Society of Health-System Pharmacists |url-status=live |archive-url=https://web.archive.org/web/20161220231218/https://www.drugs.com/monograph/fluconazole.html |archive-date=20 December 2016}}</ref>

In 1986, Pfizer acquired the worldwide rights to Zithromax ([[azithromycin]]), a macrolide antibiotic that is recommended by the [[Infectious Disease Society of America]] as a first line treatment for certain cases of community-acquired pneumonia, from [[Pliva]].<ref name="best">{{cite web |url=https://www.wipo.int/ipadvantage/en/details.jsp?id=906 |title=Azithromycin: A world best-selling Antibiotic |publisher=[[World Intellectual Property Organization]]}}</ref><ref>{{Cite journal |vauthors=Mandell LA, Wunderink RG, Anzueto A, etal |date=March 2007 |title=Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults |url=https://www.thoracic.org/statements/resources/mtpi/idsaats-cap.pdf |journal=Clinical Infectious Diseases |volume=44 |issue=Suppl 2 |pages=S27–72 |doi=10.1086/511159 |pmc=7107997 |pmid=17278083}}</ref>

In 1989, Pfizer scientists Peter Dunn and Albert Wood created Viagra ([[sildenafil]]) for treating [[high blood pressure]] and [[angina]], a chest pain associated with [[coronary artery disease]]. In 1991, it was patented in the United Kingdom as a heart medication. Early trials for the medication showed that it did not work for the treatment of heart disease, but volunteers in the clinical trials had increased [[erection]]s several days after taking the drug. It was patented in the United States in 1996 and received approval by the [[Food and Drug Administration]] in March 1998. In December 1998, Pfizer hired [[Bob Dole]] as a spokesperson for the drug.<ref>{{Cite news |url=https://www.cnn.com/2013/03/27/health/viagra-anniversary-timeline/index.html |title=Viagra: The little blue pill that could |first=Jacque |last=Wilson |work=[[CNN]] |date=March 27, 2013}}</ref> The patents for Viagra expired in 2020.<ref>{{Cite news |url=https://www.theguardian.com/science/2019/jun/09/race-to-replace-viagra-patents-erectile-dysfunction-drug-medical-research-cialis-eroxon |title=The race to replace Viagra |first=David |last=Cox |work=[[The Guardian]] |date=June 9, 2019}}</ref>

In 1991, [[William C. Steere, Jr.]] became [[chief executive officers]] of the company, succeeding [[Edmund T. Pratt Jr.]]<ref>{{Cite news |url=https://www.latimes.com/archives/la-xpm-1991-03-29-fi-903-story.html |title=Pfizer Inc., New York, has elected its... |work=[[Los Angeles Times]] |date=March 29, 1991}}</ref>

In 1991 Pfizer also began marketing Zoloft ([[sertraline]]), an [[antidepressant]] of the [[selective serotonin reuptake inhibitor]] (SSRI) class developed nine years earlier by Pfizer chemists [[Kenneth Koe]] and Willard Welch. Sertraline is primarily prescribed for [[major depressive disorder]] in adult [[outpatients]] as well as [[obsessive-compulsive disorder]], [[panic disorder]], and [[social anxiety disorder]] in both adults and children. In 2005, the year before it became a generic drug, sales were over $3{{nbsp}}billion and over 100{{nbsp}}million people had been treated with the drug.<ref>{{Cite web |date=December 2015 |title=Kenneth Koe '45 |url=https://www.reed.edu/reed-magazine/in-memoriam/obituaries/_online_only/kenneth-koe-1945.html |url-status=live |access-date=2021-05-18 |website=Reed Magazine |publisher=[[Reed College]] |archive-url=https://web.archive.org/web/20220414055337/https://www.reed.edu/reed-magazine/in-memoriam/obituaries/_online_only/kenneth-koe-1945.html |archive-date=2022-04-14}}</ref> The patent for Zoloft expired in the summer of 2006.<ref>{{Cite news |last=Smith |first=Aaron |date=2006-04-04 |title=Who stands to gain when Zoloft goes generic? |work=[[CNN Money]] |url=https://money.cnn.com/2006/04/04/news/companies/antidepressants/ |access-date=2021-05-18}}</ref>

In 1996, [[Eisai (company)|Eisai]], in partnership with Pfizer, received [[Approved drug|approval]] from the [[Food and Drug Administration]] for [[donepezil]] under the brand Aricept for treatment of [[Alzheimer's disease]];<ref>{{Cite web |title=Highlights of Prescribing Information |url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020690s035,021720s008,022568s005lbl.pdf |publisher=[[Food and Drug Administration]]}}{{dead link|date=May 2025|bot=medic}}{{cbignore|bot=medic}}</ref> Pfizer also received approval for Norvasc ([[amlodipine]]), an [[antihypertensive]] drug of the dihydropyridine calcium channel blocker class.<ref>{{Cite web |title=Drug Approval Package |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/19-787s007_Amlodipine.cfm |publisher=[[Food and Drug Administration]]}}</ref>

[[File:Zoloft bottles.jpg|thumb|right|Bottles of Zoloft ([[sertraline]]), an [[antidepressant]]]]
In 1997, the company entered into a co-marketing agreement with [[Warner–Lambert]] for Lipitor ([[atorvastatin]]), a [[statin]] for the treatment of [[hypercholesterolemia]]. Although atorvastatin was the fifth [[statin]] to be developed, clinical trials showed that atorvastatin caused a more dramatic reduction in [[low-density lipoprotein]] pattern C (LDL-C) than the other statin drugs. Upon its patent expiration in 2011, Lipitor was the best-selling drug ever, with approximately $125{{nbsp}}billion in sales over 14.5 years.<ref>{{Cite news |last=Mehta |first=Praful |date=2011-11-29 |title=Lipitor Patent Expiration – The End of an Era for Atorvastatin Sales |work=[[IHS Markit]] |url=https://ihsmarkit.com/research-analysis/lipitor-patent-expiration-atorvastatin-sales.html |access-date=2021-05-18 |archive-date=May 18, 2021 |archive-url=https://web.archive.org/web/20210518220335/https://ihsmarkit.com/research-analysis/lipitor-patent-expiration-atorvastatin-sales.html }}</ref>

=== 2000–2010: Further expansion ===
In 2001, [[Henry McKinnell]] became [[chief executive officer]] of the company, replacing [[William C. Steere, Jr.]]<ref name="longshot">{{Cite news |url=https://www.nytimes.com/2006/07/29/business/29pfizer.html |title=A Long Shot Becomes Pfizer's Latest Chief Executive |first=Alex |last=Berenson |author-link=Alex Berenson |work=[[The New York Times]] |date=July 29, 2006 |url-access=limited}}</ref>

In 2002, The [[Bill & Melinda Gates Foundation]] purchased stock in Pfizer.<ref>{{Cite news |last1=Bank |first1=David |last2=Buckman |first2=Rebecca |date=2002-05-17 |title=Gates Foundation Buys Stakes in Drug Makers |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/SB1021577629748680000 |access-date=2022-06-14 |issn=0099-9660}}</ref>

In 2004, the company received approval for Lyrica ([[pregabalin]]), an [[anticonvulsant]] and [[anxiolytic]] medication used to treat [[epilepsy]], [[neuropathic pain]], [[fibromyalgia]], [[restless leg syndrome]], and [[generalized anxiety disorder]].<ref>{{Cite web |title=Pregabalin |url=https://www.drugs.com/monograph/pregabalin.html |publisher=[[American Society of Health-System Pharmacists]]}}</ref><ref>{{cite journal |last1=Frampton |first1=James E. |title=Pregabalin: A Review of its Use in Adults with Generalized Anxiety Disorder |journal=CNS Drugs |date=September 2014 |volume=28 |issue=9 |pages=835–854 |doi=10.1007/s40263-014-0192-0 |pmid=25149863 |s2cid=5349255}}</ref><ref>{{cite journal |last1=Iftikhar |first1=I. H. |last2=Alghothani |first2=L. |last3=Trotti |first3=L. M. |title=Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis |journal=[[European Journal of Neurology]] |date=December 2017 |volume=24 |issue=12 |pages=1446–1456 |doi=10.1111/ene.13449 |pmid=28888061 |s2cid=22262972}}</ref> The United States patent on Lyrica was challenged by generic manufacturers and was upheld in 2014, extending the expiration date to 2018.<ref>{{Cite news |last=Decker |first=Susan |date=February 6, 2014 |title=Pfizer Wins Ruling to Block Generic Lyrica Until 2018 |work=[[Bloomberg News]] |url=https://www.bloomberg.com/news/2014-02-06/pfizer-wins-ruling-to-block-generic-lyrica-until-2018.html |url-access=subscription}}</ref>

In July 2006, [[Jeff Kindler]] was named [[chief executive officer]] of the company, replacing [[Henry McKinnell]].<ref name="longshot" /><ref>{{Cite news |date=July 28, 2006 |title=Pfizer names new CEO |work=[[CNN]] |url=https://money.cnn.com/2006/07/28/news/companies/pfizer_ceo/index.htm}}</ref>

On December 3, 2006, Pfizer ceased development of [[torcetrapib]], a drug that increases production of [[high density lipoprotein|HDL]], which reduces [[low density lipoprotein|LDL]] thought to be correlated to heart disease. During a [[Phase III clinical trial]] involving 15,000 patients, more deaths than expected occurred in the group that took the medicine, and the [[mortality rate]] of patients taking the combination of torcetrapib and Lipitor (82 deaths during the study) was 60% higher than those taking Lipitor alone (52 deaths during the study). Lipitor alone was not implicated in the results, but Pfizer lost nearly $1{{nbsp}}billion developing the failed drug and its stock price dropped 11% on the day of the announcement.<ref>{{Cite news |last1=Berenson |first1=Alex |last2=Pollack |first2=Andrew |date=December 5, 2006 |title=Pfizer Shares Plummet on Loss of a Promising Heart Drug |work=[[The New York Times]] |url=https://www.nytimes.com/2006/12/05/health/05pfizer.html |url-access=limited}}</ref><ref>{{Cite news |last=Berenson |first=Alex |date=December 3, 2006 |title=Pfizer Ends Studies on Drug for Heart Disease |work=[[The New York Times]] |url=https://www.nytimes.com/2006/12/03/health/03pfizer.html |url-access=limited |author-link=Alex Berenson}}</ref><ref>{{Cite news |last=Agovino |first=Theresa |date=December 3, 2006 |title=Pfizer ends cholesterol drug development |publisher=[[The Seattle Times]] |agency=[[Associated Press]] |url=https://www.seattletimes.com/nation-world/cholesterol-drug-trials-are-halted/}}</ref><ref>{{cite journal |last1=Tanne |first1=Janice Hopkins |title=Pfizer stops clinical trials of heart drug |journal=BMJ |date=16 December 2006 |volume=333 |issue=7581 |pages=1237.2–1237 |doi=10.1136/bmj.39059.438044.DB |pmid=17170401 |pmc=1702474}}</ref>

Between 2007 and 2010, Pfizer spent $3.3{{nbsp}}million on investigations and legal fees and recovered about $5.1{{nbsp}}million, and had another $5{{nbsp}}million of pending recoveries from civil lawsuits against makers of [[counterfeit]] prescription drugs. Pfizer has hired customs and narcotics experts worldwide to track down fakes and assemble evidence that can be used to pursue civil suits for [[trademark infringement]].<ref>{{Cite news |last=Bennett |first=Simeon |date=July 8, 2010 |title=Pfizer: Civil Suits for Drug Counterfeiters |work=[[Bloomberg Businessweek]] |url=https://www.bloomberg.com/news/articles/2010-07-08/pfizer-civil-suits-for-drug-counterfeiters |url-access=limited}}</ref>

In July 2008, Pfizer announced 275 job cuts at its manufacturing facility in [[Portage, Michigan]]. Portage was previously the world headquarters of [[Upjohn Company]], which had been acquired as part of Pharmacia.<ref>{{Cite news |last=Jones |first=Al |date=July 15, 2008 |title=Pfizer job cuts don't equal a reduction in work load, says company spokesman |work=[[Booth Newspapers]] |url=https://www.mlive.com/kzgazette/2008/07/pfizer_job_cuts_dont_equal_a_r.html}}</ref><ref name=":0">{{Cite news |date=April 16, 2003 |title=It's official: Pfizer buys Pharmacia |work=[[CNN]] |url=https://money.cnn.com/2003/04/16/news/companies/pfizer_pharma/}}</ref>

==== Acquisitions and mergers ====
In June 2000, Pfizer acquired Warner-Lambert outright for $116{{nbsp}}billion. To satisfy conditions imposed by antitrust regulators at the [[Federal Trade Commission]], Pfizer sold off or transferred stakes in several minor products, including RID (a shampoo for treatment of [[Head lice infestation|head lice]], sold to [[Bayer]]) and Warner-Lambert's antidepressant [[Celexa]] (which competes with Zoloft).<ref>{{Cite news |last=Hensley |first=Scott |date=June 20, 2000 |title=Pfizer Completes Stormy Takeover Of Warner-Lambert for $116 Billion |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/SB961456765639278103 |url-access=subscription}}</ref> The acquisition created what was, at the time, the second-largest pharmaceutical company worldwide.<ref>{{Cite news |last=Campbell |first=Todd |date=May 15, 2017 |title=Here are the 7 biggest mergers of all time |publisher=[[Business Insider]] |agency=[[The Motley Fool]] |url=https://www.businessinsider.com/here-are-the-7-biggest-mergers-of-all-time-2017-5#6-warner-lambert-warms-up-to-pfizer-89-billion-2}}</ref>

In 2003, Pfizer merged with [[Pharmacia]], and in the process acquired [[G.D. Searle, LLC|Searle]] and [[SUGEN]]. Searle had developed Flagyl ([[metronidazole]]), a [[nitroimidazole]] antibiotic medication used particularly for [[anaerobe|anaerobic]] [[bacterium|bacteria]] and [[protozoa]].<ref name=":0" /><ref>{{Cite web |title=Metronidazole Monograph for Professionals |url=https://www.drugs.com/monograph/metronidazole.html |publisher=[[Drugs.com]]}}</ref> Searle also developed [[celecoxib]] (Celebrex) a [[COX-2 inhibitor]] and [[nonsteroidal anti-inflammatory drug]] (NSAID) used to treat the [[pain]] and [[inflammation]] in [[osteoarthritis]], [[acute pain]] in adults, [[rheumatoid arthritis]], [[ankylosing spondylitis]], [[painful menstruation]], and [[juvenile rheumatoid arthritis]].<ref>{{cite web |date=11 November 2019 |title=Celecoxib Monograph for Professionals |url=https://www.drugs.com/monograph/celecoxib.html |website=Drugs.com |publisher=American Society of Health-System Pharmacists}}</ref> [[SUGEN]], a company focused on [[protein kinase]] inhibitors, had pioneered the use of ATP-mimetic small molecules to block [[signal transduction]]. The [[SUGEN]] facility was shut down in 2003 by Pfizer, with the loss of more than 300 jobs, and several programs were transferred to Pfizer. These included [[sunitinib]] (Sutent), a cancer medication which was approved for human use by the FDA in January 2006.<ref>{{Cite news |url=https://www.bloomberg.com/news/articles/2005-11-20/the-spirit-of-a-startup-lives-on |title=The Spirit Of A Startup Lives On |work=[[Bloomberg Businessweek]] |date=November 21, 2005}}</ref><ref>{{Cite news |url=https://www.bizjournals.com/sanfrancisco/stories/2003/04/28/daily24.html |title=Pfizer expects to shutter South City biotech outpost |work=[[American City Business Journals]] |date=April 30, 2003}}</ref> A related compound, SU11654 ([[Toceranib]]), was also approved for [[cancer in dogs]], and the [[ALK inhibitor]] [[Crizotinib]] also grew out of a SUGEN program.<ref>{{Cite news |url=https://www.wsj.com/articles/SB10001424053111904009304576532892704206326 |title=FDA Approves Pfizer Lung-Cancer Drug |first=Jonathan D. |last=Rockoff |work=[[The Wall Street Journal]] |date=August 26, 2011 |url-access=subscription}}</ref><ref>{{cite book |doi=10.1016/B978-0-12-409547-2.12391-1 |chapter=Selective Kinase Inhibitors in Cancer |title=Comprehensive Medicinal Chemistry III |year=2017 |last1=Mortlock |first1=A.A. |last2=Wilson |first2=D.M. |last3=Kettle |first3=J.G. |last4=Goldberg |first4=F.W. |last5=Foote |first5=K.M. |pages=39–75 |isbn=978-0-12-803201-5}}</ref>

In October 2006, the company announced it would acquire PowerMed.<ref>{{Cite news |last=Barriaux |first=Marianne |date=October 9, 2006 |title=Pfizer buys vaccine developer PowderMed |work=[[The Guardian]] |url=https://www.theguardian.com/business/2006/oct/09/money5}}</ref>

On October 15, 2009, Pfizer acquired [[Wyeth]] for $68{{nbsp}}billion in cash and stock, including the assumption of debt, making Pfizer the largest pharmaceutical company in the world.<ref>{{Cite news |last1=Sorkin |first1=Andrew Ross |last2=Wilson |first2=Duff |date=January 25, 2009 |title=Pfizer Agrees to Pay $68 Billion for Rival Drug Maker Wyeth |work=[[The New York Times]] |url=https://www.nytimes.com/2009/01/26/business/26drug.html |url-access=limited |issn=0362-4331 |author-link1=Andrew Ross Sorkin |author-link2=Duff Wilson}}</ref><ref>{{Cite news |date=October 15, 2009 |title=Pfizer completes $67 billion deal for rival Wyeth |work=[[Reuters]] |url=https://www.reuters.com/article/instant-article/idUSTRE59E4S320091015}}</ref><ref>{{cite news |last1=Karnitschnig |first1=Matthew |last2=Rockoff |first2=Jonathan D. |date=January 23, 2009 |title=Pfizer in Talks to Buy Wyeth |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/SB123268511212809429 |url-access=subscription}}</ref><ref name="worst">{{Cite news |last=Edwards |first=Jim |date=January 23, 2009 |title=The Pfizer–Wyeth Deal Worst-Case Scenario |work=[[CBS News]] |url=https://www.cbsnews.com/news/the-pfizer-wyeth-deal-worst-case-scenario/}}</ref><ref name="wyethpr">{{Cite press release |title=PFIZER COMPLETES ACQUISITION OF WYETH |url=https://www.pfizer.com/news/press-release/press-release-detail/pfizer_completes_acquisition_of_wyeth |publisher=Pfizer |date=October 14, 2009}}</ref> The acquisition of Wyeth provided Pfizer with a [[pneumococcal conjugate vaccine]], trademarked [[Pneumococcal conjugate vaccine#Prevnar|Prevnar 13]]; this is used for the prevention of invasive pneumococcal infections. The introduction of the original, 7-valent version of the vaccine, developed by [[Wyeth]] in February 2000, led to a 75% reduction in the incidence of invasive pneumococcal infections among children under age{{nbsp}}5 in the United States. Pfizer introduced an improved version of the vaccine in 2010, for which it was granted a patent in India in 2017. Prevnar 13 provides coverage of 13 bacterial variants, expanding beyond the original 7-valent version.<ref name="wyethpr" /> By 2012, the rate of invasive infections among children under age{{spaces}}5 had been reduced by an additional 50%.<ref name="cdc.gov">{{Cite web |date=April 5, 2019 |title=CDC – ABCs: Surveillance Reports main page – Active Bacterial Core surveillance |url=https://www.cdc.gov/abcs/reports-findings/surv-reports.html}}</ref><ref>{{Cite web |last=Herper |first=Matthew |date=August 24, 2020 |title=In the race for a Covid-19 vaccine, Pfizer turns to a scientist with a history of defying skeptics – and getting results |url=https://www.statnews.com/2020/08/24/pfizer-edge-in-the-race-for-a-covid-19-vaccine-could-be-a-scientist-with-two-best-sellers-to-her-credit/ |website=[[Stat (website)|Stat]]}}</ref>

=== 2010–2020: Further discoveries and acquisitions ===
[[File:235 E42 St 2025 jeh.jpg|thumb|Former headquarters on 42nd Street]]
[[File:Pfizer World Headquarters (51921996957).jpg|thumb|Entrance to former Pfizer World Headquarters building (1961–2023)]]
In 2010, [[Ian Read]] was named [[chief executive officer]] of the company.<ref>{{Cite press release |url=https://www.carlyle.com/media-room/news-release-archive/carlyle-group-names-former-pfizer-chairman-and-ceo-ian-read |title=The Carlyle Group Names Former Pfizer Chairman and CEO Ian Read as an Operating Executive for Global Healthcare |publisher=[[The Carlyle Group]] |date=January 8, 2020}}</ref>

In February 2011, Pfizer announced the closure of its UK research and development facility (formerly also a manufacturing plant) in [[Sandwich, Kent]], which at the time employed 2,400 people.<ref>{{Cite news |url=https://www.bbc.co.uk/news/business-12335801 |title=Pfizer to close UK research site |work=[[BBC News]] |date=February 1, 2011}}</ref> In March 2011, Pfizer acquired [[King Pharmaceuticals]] for $3.6{{nbsp}}billion in cash. King produced emergency injectables such as the [[EpiPen]].<ref>{{Cite news |url=https://www.modernhealthcare.com/article/20110301/NEWS/303019922/pfizer-closes-king-pharmaceuticals-acquisition |title=Pfizer closes King Pharmaceuticals acquisition |first=Maureen |last=Mckinney |work=[[Modern Healthcare]] |date=March 1, 2011}}</ref>

On September 4, 2012, the FDA approved [[bosutinib]] (Bosulif) for [[chronic myelogenous leukemia]] (CML), a rare type of [[leukemia]] and a blood and [[bone marrow]] disease that affects primarily older adults.<ref>{{Cite news |url=https://www.reuters.com/article/us-pfizer-leukemia/fda-approves-pfizer-leukemia-drug-idUSBRE88314720120904 |title=FDA approves Pfizer leukemia drug |first=Anna |last=Yukhananov |work=[[Reuters]] |date=September 4, 2012}}</ref> In November 2012, Pfizer received approval from the [[Food and Drug Administration]] for Xeljanz, a [[tofacitinib]], for [[rheumatoid arthritis]] and [[ulcerative colitis]].<ref>{{Cite web |url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214orig1s000toc.cfm |archive-url=https://web.archive.org/web/20150120070754/http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203214Orig1s000TOC.cfm |archive-date=January 20, 2015 |title=Drug Approval Package |publisher=[[Food and Drug Administration]]}}</ref> The drug had sales of $1.77{{nbsp}}billion in 2018, and in January 2019, it was the top drug in the United States for [[direct-to-consumer advertising]], passing [[adalimumab]] (Humira).<ref>{{Cite magazine |title=Pfizer switches RA patients to lower dose of fast-growing Xeljanz as safety issues arise in postmarketing study |url=https://www.fiercepharma.com/pharma/postmarketing-study-pfizer-switches-ra-patients-to-lower-xeljanz-dose-safety-concerns |magazine=Fierce Pharma | publisher=[[Questex]] | first=Eric |last=Sagonowsky |date=February 20, 2019}}</ref> In 2023, the Institute for Clinical and Economic Review (ICER) identified Xeljanz (tofacitinib) as one of five high-expenditure drugs that experienced significant net price increases without new clinical evidence to justify the hikes. Specifically, Xeljanz's wholesale acquisition cost rose by 6%, leading to an additional $72 million in costs to U.S. payers.<ref>{{Cite web |title=Institute for Clinical and Economic Review Announces Most Significant Drug-Price Hikes Unsupported by New Clinical Evidence in US |url=https://icer.org/news-insights/press-releases/icer-announces-most-significant-drug-price-hikes-unsupported-by-new-clinical-evidence-in-us/?mkt_tok=NjM4LVBYUi0zMTgAAAGYMxe5Fv3mzhJbiVnr0V4g2FUAcS3PgZOZSYRvQcW3_VFPXIet0TCD7bWAyVVeW2Q62e3AynO8rDpP8sIoIbs_qux8kQcMBBD4cDSe3Q |access-date=2025-02-06 |website=ICER |language=en-US}}</ref>

On February 1, 2013, [[Zoetis]], the Agriculture Division of Pfizer and later Pfizer Animal Health, became a [[public company]] via an [[initial public offering]], raising $2.2{{nbsp}}billion.<ref>{{Cite press release |title=Zoetis™ Files IPO Registration Statement |url=https://www.zoetisus.com/news-and-media/zoetis-files-ipo-registration-statement.aspx |publisher=[[Business Wire]] |date=August 13, 2012}}</ref><ref>{{Cite news |url=https://dealbook.nytimes.com/2013/02/01/shares-of-zoetis-surge-on-debut/ |last=J. de la Merced |first=Michael |title=Shares of Zoetis Surge on Debut |work=[[The New York Times]] |date=February 1, 2013 |url-access=limited}}</ref><ref>{{Cite news |title=Zoetis Raises $2.2 Billion in IPO |url=https://www.wsj.com/articles/SB10001424127887323701904578276530830057770 |last=Dieterich |first=Chris |work=[[The Wall Street Journal]] |date=January 31, 2013 |url-access=subscription}}</ref><ref>{{Cite news |url=https://www.cbsnews.com/news/shares-of-animal-health-company-zoetis-soar-in-ipo/ |title=Shares of animal health company Zoetis soar in IPO |agency=[[Associated Press]] |publisher=[[CBS News]] |date=February 1, 2013}}</ref> Later in 2013, Pfizer completed the [[corporate spin-off]] of its remaining stake in [[Zoetis]].<ref>{{Cite news |url=https://www.wsj.com/articles/SB10001424127887323975004578498994013821124 |title=Pfizer to Spin Off Remaining Zoetis Stake |first=Peter |last=Loftus |work=[[The Wall Street Journal]] |date=May 22, 2013}}</ref><ref>{{Cite news |url=https://www.reuters.com/article/us-pfizer-zoetis/pfizer-to-spin-off-zoetis-stake-to-shareholders-idUSBRE94L0JB20130522 |title=Pfizer to spin off Zoetis stake to shareholders |first1=Caroline |last1=Humer |first2=Ransdell |last2=Pierson |work=[[Reuters]] |date=May 22, 2013}}</ref>

In September 2014, the company acquired Innopharma for $225{{nbsp}}million, plus up to $135{{nbsp}}million in milestone payments, in a deal that expanded Pfizer's range of generic and injectable drugs.<ref>{{Cite magazine |url=https://www.fiercepharma.com/pharma/pfizer-completes-acquisition-of-innopharma |title=Pfizer Completes Acquisition Of InnoPharma |first=Emily |last=Wasserman |magazine=Fierce Pharma | publisher=[[Questex]] |date=September 29, 2014}}</ref><ref>{{Cite news |title=Pfizer to Acquire InnoPharma for Up to $360M |url=https://www.genengnews.com/news/pfizer-to-acquire-innopharma-for-up-to-360m/ |website=genengnews.com |date=July 16, 2014}}</ref>

On January 5, 2015, the company announced it would acquire a controlling interest in Redvax, expanding its vaccine portfolio targeting human [[cytomegalovirus]].<ref>{{Cite news |title=Pfizer Buys Redvax, Boosting Vaccine Portfolio |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-redvax-boosting-vaccine-portfolio/ |website=genengnews.com |date=January 5, 2015}}</ref> In February 2015, the company received approval from the [[Food and Drug Administration]] for [[palbociclib]] (Ibrance) for treatment of certain types of [[breast cancer]].<ref>{{cite journal|display-authors=3 |last1=Beaver |first1=Julia A. |last2=Amiri-Kordestani |first2=Laleh |last3=Charlab |first3=Rosane |last4=Chen |first4=Wei |last5=Palmby |first5=Todd |last6=Tilley |first6=Amy |last7=Zirkelbach |first7=Jeanne Fourie |last8=Yu |first8=Jingyu |last9=Liu |first9=Qi |last10=Zhao |first10=Liang |last11=Crich |first11=Joyce |last12=Chen |first12=Xiao Hong |last13=Hughes |first13=Minerva |last14=Bloomquist |first14=Erik |last15=Tang |first15=Shenghui |last16=Sridhara |first16=Rajeshwari |last17=Kluetz |first17=Paul G. |last18=Kim |first18=Geoffrey |last19=Ibrahim |first19=Amna |last20=Pazdur |first20=Richard |last21=Cortazar |first21=Patricia |title=FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer |journal=Clinical Cancer Research |date=1 November 2015 |volume=21 |issue=21 |pages=4760–4766 |doi=10.1158/1078-0432.CCR-15-1185 |pmid=26324739 |s2cid=24762535 |doi-access=free}}</ref><ref>{{Cite web |url=https://www.fda.gov/drugs/resources-information-approved-drugs/palbociclib-ibrance |title=Palbociclib (IBRANCE) |date=February 9, 2019 |publisher=[[Food and Drug Administration]]}}{{dead link|date=May 2025|bot=medic}}{{cbignore|bot=medic}}</ref> In March 2015, the company announced it would restart its collaboration with [[Eli Lilly and Company]] surrounding the [[Phase III trial]] of [[Tanezumab]].<ref>{{Cite news |title=Pfizer, Lilly to Resume Phase III Tanezumab Clinical Program |url=https://www.genengnews.com/topics/drug-discovery/pfizer-lilly-to-resume-phase-iii-tanezumab-clinical-program/ |website=genengnews.com |date=March 23, 2015}}</ref> In May 2015, Pfizer and a [[Bar-Ilan University]] laboratory announced a partnership based on the development of medical [[DNA nanotechnology]].<ref>{{Cite news |last=Gali |first=Weinreb |title=Pfizer to collaborate on Bar-Ilan DNA robots |work=[[Globes (newspaper)|Globes]] |url=https://en.globes.co.il/en/article-pfizer-to-collaborate-on-bar-ilan-dna-robots-1001036703 |date=May 14, 2015}}</ref> In June 2015, the company acquired Nimenrix and Mencevax, [[meningococcal vaccine]]s, from GlaxoSmithKline for around $130{{nbsp}}million.<ref>{{Cite news |title=Pfizer Buys Two GSK Meningitis Vaccines for $130M |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-two-gsk-meningitis-vaccines-for-130m/ |website=genengnews.com |date=June 22, 2015}}</ref> In September 2015, Pfizer acquired [[Hospira]] for $17{{nbsp}}billion, including the assumption of debt.<ref>{{Cite news |url=https://www.thepharmaletter.com/article/pfizer-completes-17-billion-hospira-acquisition |title=Pfizer completes $17-billion Hospira acquisition |work=[[The Pharma Letter]] |date=September 4, 2015}}</ref> [[Hospira]] was the largest producer of generic injectable pharmaceuticals in the world.<ref>{{Cite news |title=US-based Hospira to buy Orchid Chemicals' injectables biz for $400 mn |url=https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/us-based-hospira-to-buy-orchid-chemicals-injectables-biz-for-400-mn/articleshow/5342003.cms |first1=Mohit |last1=Bhalla |first2=Khomba |last2=Singh |work=[[The Economic Times]] |date=December 16, 2009}}</ref> On November 23, 2015, Pfizer and [[Allergan]] announced a planned $160{{nbsp}}billion merger, in the largest pharmaceutical deal ever and the third largest corporate merger in history. The proposed transaction contemplated that the merged company maintain Allergan's [[Republic of Ireland]] domicile, resulting in the new company being subject to [[corporation tax]] at the relatively low rate of 12.5%.<ref>{{Cite news |title=Pfizer seals $160bn Allergan deal to create drugs giant |url=https://www.bbc.co.uk/news/business-34900344 |work=[[BBC News]] |date=November 23, 2015}}</ref> The deal was to constitute a [[reverse merger]], whereby Allergan acquired Pfizer, with the new company then changing its name to "Pfizer, plc".<ref>{{Cite news |title=Pfizer to buy Allergan in $160 billion deal |url=https://www.reuters.com/article/us-allergan-m-a-pfizer/pfizer-to-buy-allergan-in-160-billion-deal-idUSKBN0TB0UT20151124 |first1=Ransdell |last1=Pierson |first2=Bill |last2=Berkrot |work=[[Reuters]] |date=November 24, 2015}}</ref><ref>{{Cite news |title=Pfizer to Acquire Allergan for $160B |url=https://www.genengnews.com/news/pfizer-to-acquire-allergan-for-160b/ |work=genengnews.com |date=November 23, 2015}}</ref><ref>{{Cite news |first=Cynthia |last=Koons |title=Pfizer and Allergan to Combine With Joint Value of $160 Billion |url=https://www.bloomberg.com/news/articles/2015-11-22/pfizer-allergan-said-to-be-close-to-150-billion-merger |work=[[Bloomberg News]] |date=November 22, 2015 |url-access=limited}}</ref> On April 6, 2016, Pfizer and Allergan terminated the merger agreement after the [[Obama administration]] and the [[United States Department of the Treasury]] introduced new laws intended to limit [[corporate inversion]]s (the extent to which companies could move their headquarters overseas in order to reduce the amount of taxes they pay).<ref>{{Cite news |last=Bray |first=Chad |title=Pfizer and Allergan Call Off Merger After Tax-Rule Changes |url=https://www.nytimes.com/2016/04/07/business/dealbook/pfizer-allergan-merger.html |work=[[The New York Times]] |date=April 6, 2016 |url-access=limited}}</ref><ref>{{Cite news |last1=Humer |first1=Caroline |last2=Banerjee |first2=Ankur |title=Pfizer, Allergan scrap $160 billion deal after U.S. tax rule change |work=[[Reuters]] |url=https://www.reuters.com/article/us-allergan-m-a-pfizer-idUSKCN0X3188 |date=April 6, 2016}}</ref>

In June 2016, the company acquired Anacor Pharmaceuticals for $5.2{{nbsp}}billion, expanding its portfolio in both inflammation and immunology drugs areas.<ref>{{Cite news |title=Pfizer to Acquire Anacor Pharmaceuticals for $5.2B |url=https://www.genengnews.com/news/pfizer-to-acquire-anacor-pharmaceuticals-for-5-2b/ |website=genengnews.com |date=May 16, 2016}}</ref> In August 2016, the company made a $40{{nbsp}}million bid for the assets of BIND Therapeutics, which was in [[bankruptcy]].<ref>{{Cite news |title=Pfizer Places High Bid of $40M for BIND Therapeutics |url=https://www.genengnews.com/news/pfizer-places-high-bid-of-40m-for-bind-therapeutics/ |website=genengnews.com |date=July 27, 2016}}</ref> The same month, the company acquired Bamboo Therapeutics for $645{{nbsp}}million, expanding its gene therapy offerings.<ref>{{Cite news |title=Pfizer Acquires Bamboo Therapeutics in a $645M Deal |url=https://www.genengnews.com/news/pfizer-acquires-bamboo-therapeutics-in-a-645m-deal/ |website=genengnews.com |date=August 1, 2016}}</ref> In September 2016, the company acquired cancer drug-maker [[Medivation]] for $14{{nbsp}}billion.<ref>{{Cite news |title=Pfizer to Acquire Medivation for $14B |url=https://www.genengnews.com/news/pfizer-to-acquire-medivation-for-14b/ |website=genengnews.com |date=August 22, 2016}}</ref><ref>{{Cite news |title=Pfizer to buy cancer drug firm Medivation for $14bn |work=[[BBC News]] |url=https://www.bbc.co.uk/news/business-37150531 |date=August 22, 2016}}</ref> In October 2016, the company licensed the anti-[[CTLA4]] monoclonal antibody, ONC-392, from OncoImmune.<ref>{{Cite news |url=https://www.genengnews.com/topics/drug-discovery/oncoimmune-licenses-onc-392-to-pfizer-for-up-to-250m/ |title=OncoImmune Licenses ONC-392 to Pfizer for Up to $250M |work=genengnews.com |date=October 15, 2016}}</ref> In November 2016, Pfizer funded a $3,435,600 study with the [[CDC Foundation]] to research "screen-and-treat" strategies for [[cryptococcal disease]] in [[Botswana]].<ref name=":4">{{Cite web |date=2021-12-09 |title=CDC Foundation Active Programs October 1, 2020 – September 30, 2021 |url=https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |url-status=live |archive-url=https://web.archive.org/web/20220115161004/https://www.cdcfoundation.org/CDCF-ActivePrograms-CDC-FY21?inline |archive-date=2022-01-15 |access-date=2022-08-06 |website=[[CDC Foundation]]}}</ref> In December 2016, Pfizer acquired [[AstraZeneca]]'s small-molecule antibiotics business for $1.575 billion.<ref>{{Cite news |title=Pfizer Buys AstraZeneca Antibiotics for Up to $1.575B |url=https://www.genengnews.com/topics/drug-discovery/pfizer-buys-astrazeneca-antibiotics-for-up-to-1-575b/ |website=genengnews.com |date=August 24, 2016}}</ref><ref>{{Cite magazine |title=Pfizer grabs AZ antibiotics in $1.5B deal. Pre-split prep or just another sales-boosting buy? |url=https://www.fiercepharma.com/pharma/pfizer-grabs-az-antibiotics-1-5b-deal-pre-split-prep-or-just-another-sales-boosting-buy |first=Tracy |last=Staton |magazine=Fierce Pharma | publisher=[[Questex]] |date=August 24, 2016}}</ref>

In January 2018, Pfizer announced that it would end its work on research into treatments for [[Alzheimer's disease]] and [[Parkinsonism]] (a symptom of [[Parkinson's disease]] and other conditions). The company said about 300 researchers would lose their jobs.<ref>{{Cite news |last=Hiltzik |first=Michael | author-link=Michael Hiltzik |title=Pfizer, pocketing a big tax cut from Trump, will end investment in Alzheimer's and Parkinson's research |url=https://www.latimes.com/business/hiltzik/la-fi-hiltzik-pfizer-20180108-story.html |work=[[Los Angeles Times]] |date=January 8, 2018 |url-access=subscription}}</ref> In July 2018, the [[Food and Drug Administration]] approved [[enzalutamide]], developed by Pfizer and [[Astellas Pharma]] for patients with [[castration]]-resistant [[prostate cancer]].<ref>{{Cite press release |url=https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-castration-resistant-prostate-cancer |title=FDA approves enzalutamide for castration-resistant prostate cancer |publisher=[[Food and Drug Administration]] |date=July 13, 2018}}{{dead link|date=May 2025|bot=medic}}{{cbignore|bot=medic}}</ref> In August 2018, Pfizer signed an agreement with [[BioNTech]] to conduct joint research and development activities regarding [[mRNA]]-based [[influenza vaccine]]s.<ref>{{Cite press release |title=BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza |url=https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-signs-collaboration-agreement-pfizer-develop-mrna-based |publisher=[[BioNTech]] |date=August 16, 2018 |access-date=November 12, 2020 |archive-date=November 24, 2020 |archive-url=https://web.archive.org/web/20201124191744/https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-signs-collaboration-agreement-pfizer-develop-mrna-based/ }}</ref> In October 2018, effective January 1, 2019, [[Albert Bourla]] was promoted to [[chief executive officer]], succeeding [[Ian Read]], his mentor.<ref>{{Cite news |url=https://www.reuters.com/article/us-pfizer-ceo/pfizer-to-replace-longtime-ceo-read-with-veteran-bourla-idUSKCN1MB29D |title=Pfizer to replace longtime CEO Read with veteran Bourla |first1=Tamara |last1=Mathias |first2=Ankur |last2=Banerjee |date=October 1, 2018 |work=[[Reuters]]}}</ref><ref>{{cite news |last=Maidenberg |first=Micah |title=Pfizer Prepares for CEO Transition With Executive Suite Changes |url=https://www.wsj.com/articles/pfizer-prepares-for-ceo-transition-with-executive-suite-changes-1539095075 |work=[[The Wall Street Journal]] |date=October 9, 2018 |url-access=subscription}}</ref><ref>{{cite news |url=https://www.businessinsider.com/who-is-albert-bourla-next-pfizer-ceo-2018-10 |title=Pfizer's CEO is stepping down after 8 years — meet the man who will be replacing him |last=Ramsey |first=Lydia |work=[[Business Insider]] |date=October 1, 2018 |url-access=subscription}}</ref><ref>{{cite news |last=Jarvis |first=Lisa M. |title=Pfizer unveils CEO succession plan |work=[[Chemical & Engineering News]] |url=https://cen.acs.org/pharmaceuticals/Pfizer-unveils-CEO-succession-plan/96/i40 |date=October 3, 2018}}</ref>
In July 2019, the company acquired Therachon for up to $810{{nbsp}}million, expanding its rare disease portfolio through Therachon's recombinant human fibroblast growth factor receptor 3 compound, aimed at treating conditions such as [[achondroplasia]].<ref>{{Cite news |url=https://www.spglobal.com/marketintelligence/en/news-insights/trending/sWCcSrMgL8UmeCJXuuGp-w2 |title=Pfizer completes acquisition of Therachon to bolster rare disease drug portfolio |first=Ravikash |last=Bakolia |work=[[S&P Global]] |date=July 1, 2019}}</ref> Also in July, Pfizer acquired [[Array Biopharma]] for $10.6{{nbsp}}billion, boosting its oncology pipeline.<ref>{{Cite news | url=https://www.cnbc.com/2019/06/17/pfizer-to-buy-array-biopharma-for-48-a-share-in-cash.html | title=Pfizer bolsters its cancer portfolio with a $10.64 billion deal for Array | agency=[[Reuters]] | work=[[CNBC]] | date=June 17, 2019}}</ref> In August 2019, Pfizer merged its consumer health business with that of GlaxoSmithKline, into a [[joint venture]] owned 68% by GlaxoSmithKline and 32% by Pfizer, with plans to make it a [[public company]]. The transaction built on a 2018 transaction where GlaxoSmithKline acquired [[Novartis]]' stake in the GSK-Novartis consumer healthcare joint business.<ref>{{Cite news |url=https://www.bbc.co.uk/news/business-46616713 |title=GlaxoSmithKline and Pfizer merge healthcare arms |work=[[BBC News]] |date=December 19, 2018}}</ref> The transaction followed negotiations with other companies including [[Reckitt Benckiser]],<ref>{{Cite magazine |title=Reckitt Benckiser's still keen on a Pfizer OTC buy. But can it afford one? |url=https://www.fiercepharma.com/pharma/reckitt-benckiser-s-still-keen-a-pfizer-otc-buy-but-can-it-afford-one |magazine=Fierce Pharma | publisher=[[Questex]] |first=Carly |last=Helfand |date=October 16, 2017}}</ref> [[Sanofi]], [[Johnson & Johnson]],<ref>{{Cite magazine |title=Sanofi, J&J could join GlaxoSmithKline, Reckitt in $20B bidding war for Pfizer OTC: report |url=https://www.fiercepharma.com/pharma/sanofi-j-j-could-join-gsk-reckitt-20b-bidding-war-for-pfizer-otc-report |magazine=Fierce Pharma | publisher=[[Questex]] |first=Carly |last=Helfand |date=October 26, 2017}}</ref> and [[Procter & Gamble]].<ref>{{Cite magazine |title=GlaxoSmithKline eyes Pfizer's OTC unit. But will a buy imperil its dividend? |url=https://www.fiercepharma.com/pharma/glaxosmithkline-s-eyeing-pfizer-s-otc-unit-but-will-a-buy-imperil-its-dividend |magazine=Fierce Pharma | publisher=[[Questex]] |first=Carly |last=Helfand |date=October 25, 2017}}</ref> In September 2019, Pfizer initiated a study with the [[CDC Foundation]] to investigate the tracking of [[healthcare-associated infection]]s, scheduled to run through to June 2023.<ref name=":4" /> In December 2019, Pfizer awarded the CDC Foundation a further $1,948,482 to continue its [[cryptococcal disease]] screening and treatment research in nine African countries.<ref name=":4" />

===2020–present: pandemic, corporate development, and Trump tariffs ===
====COVID-19 and vaccine development====
In March 2020, Pfizer joined the COVID-19 Therapeutics Accelerator funding vehicle to expedite development of [[Treatment and management of COVID-19|treatments against COVID-19]].<ref>{{Cite web |last=Staines |first=Richard |date=2020-03-26 |title=Pharma giants including Novartis collaborate on COVID-19 therapies |url=https://pharmaphorum.com/news/collaborate-covid19-therapies/ |url-status=live |archive-url=https://archive.today/20220118165943/https://pharmaphorum.com/news/collaborate-covid19-therapies/ |archive-date=January 18, 2022 |access-date=2022-06-06 |website=Pharmaphorum -GB }}</ref><ref>{{Cite web |title=Advancing research into accessible coronavirus treatments |url=https://www.therapeuticsaccelerator.org/ |url-status=live |archive-url=https://archive.today/20210707230649/https://www.therapeuticsaccelerator.org/ |archive-date=July 7, 2021 |access-date=2022-06-06 |website=COVID-19 Therapeutics Accelerator }}</ref> The $125 million initiative was launched by the [[Bill & Melinda Gates Foundation]] in partnership with [[Mastercard]] and [[Wellcome Trust]], with additional funding announced shortly after from [[Chan Zuckerberg Initiative]], [[Foreign, Commonwealth and Development Office|UK Foreign, Commonwealth and Development Office]] and [[Madonna]].<ref>{{Cite web |date=2020-03-10 |title=Announcing the COVID-19 Therapeutics Accelerator |url=https://www.gatesfoundation.org/ideas/articles/coronavirus-mark-suzman-therapeutics |url-status=live |archive-url=https://archive.today/20220118165008/https://www.gatesfoundation.org/ideas/articles/coronavirus-mark-suzman-therapeutics |archive-date=January 18, 2022 |access-date=2022-06-06 |website=[[Bill & Melinda Gates Foundation]] }}</ref><ref>{{Cite web |last=Au-Yeung |first=Angel |date=2020-04-03 |title=A Bill Gates-Backed Accelerator For COVID-19 Therapeutics Treatment Partners With Madonna And Mark Zuckerberg's Chan Zuckerberg Initiative |url=https://www.forbes.com/sites/angelauyeung/2020/04/03/a-bill-gates-backed-accelerator-for-covid-19-coronavirus-therapeutics-treatment-partners-with-madonna-and-mark-zuckerbergs-chan-zuckerberg-initiative/ |url-status=live |archive-url=https://archive.today/20220118165740/https://www.forbes.com/sites/angelauyeung/2020/04/03/a-bill-gates-backed-accelerator-for-covid-19-coronavirus-therapeutics-treatment-partners-with-madonna-and-mark-zuckerbergs-chan-zuckerberg-initiative/?sh=54ee18948067 |archive-date=January 18, 2022 |access-date=2022-06-06 |website=[[Forbes]] }}</ref>

The following month, the [[Foundation for the National Institutes of Health]] announced the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership to develop a coordinated research strategy for prioritizing and speeding up development of COVID-19 vaccines and pharmaceutical products.<ref>{{Cite web |title=Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) |url=https://www.nih.gov/research-training/medical-research-initiatives/activ |archive-url=https://archive.today/20220111042823/https://www.nih.gov/research-training/medical-research-initiatives/activ |archive-date=2022-01-11 |access-date=2022-06-19 |website=[[National Institutes of Health]] (NIH) }}</ref> Pfizer joined the partnership as an industry "leadership organization", and participated as a collaborator in ACTIV-led clinical trials.<ref>{{Cite web |date=2022-03-04 |author=University of Minnesota, International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), University of Copenhagen, Medical Research Council, Kirby Institute, Washington D.C. Veterans Affairs Medical Center, AIDS Clinical Trials Group |title=A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04501978}}</ref><ref>{{Cite web |last=Wholley |first=David |date=2020-06-12 |title=Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) |url=https://www.bio.org/sites/default/files/2020-06/ACTIV-BIO-webinar-6-12-20-final.pdf |url-status=live |archive-url=https://web.archive.org/web/20220326054706/https://www.bio.org/sites/default/files/2020-06/ACTIV-BIO-webinar-6-12-20-final.pdf |archive-date=2022-03-26 |access-date=2022-06-18 |website=[[Biotechnology Innovation Organization]]}}</ref> CEO [[Albert Bourla]] attended the [[GAVI]] [[COVAX AMC]] 2021 Investment Opportunity Launch Event, otherwise named One World Protected, on April 15, 2021.<ref>{{Cite web |last1=U.S. Department of State |last2=USAID |date=2021-04-15 |title=The Gavi COVAX AMC Investment Opportunity Launch Event Participant List |url=https://www.gavi.org/sites/default/files/covid/covax/Investment-Opportunity-Launch-Participant-List.pdf |url-status=live |archive-url=https://web.archive.org/web/20220821050428/https://www.gavi.org/sites/default/files/covid/covax/Investment-Opportunity-Launch-Participant-List.pdf |archive-date=2022-08-21 |access-date=2022-08-21 |website=[[Gavi, the Vaccine Alliance]]|author1-link=U.S. Department of State |author2-link=USAID }}</ref>

In Canada, Pfizer endorsed the use of a [[Vaccine passports during the COVID-19 pandemic|vaccine passport]] [[mobile app]] developed by CANImmunize in order to record and track status of COVID-19 vaccination.<ref name=":3">{{Cite web |title=Partners |url=https://www.canimmunize.ca/en/partners |url-status=live |archive-url=https://web.archive.org/web/20220517111831/https://www.canimmunize.ca/en/partners |archive-date=2022-05-17 |access-date=2022-07-01 |website=CANImmunize }}</ref>

As the scale of the [[COVID-19 pandemic]] became apparent, Pfizer partnered with BioNTech to study and develop [[COVID-19]] mRNA vaccine candidates. Unlike many of its competitors, Pfizer took no initial research funds from the United States' [[Operation Warp Speed]] vaccine development program, instead choosing to invest roughly $2 billion of its own funds. Pfizer CEO Albert Bourla has said that he declined money from Operation Warp Speed to avoid government intervention, stating later that "when you get money from someone that always comes with strings. They want to see how we are going to progress, what type of moves you are going to do. They want reports. And also, I wanted to keep Pfizer out of politics, by the way."<ref>{{Cite news |last=Czachor |first=Emily |date=2020-11-09 |title=Pfizer Avoided R&D Funding From Trump's Operation Warp Speed Because of Bureaucracy, Politics |work=[[Newsweek]] |url=https://www.newsweek.com/pfizer-avoided-rd-funding-trumps-operation-warp-speed-because-bureaucracy-politics-1546110 |access-date=2021-05-18}}</ref>

In May 2020, Pfizer began testing four different [[COVID-19 vaccine]] variations using [[lipid nanoparticle]] technology provided by Canadian biotechnology company [[Acuitas Therapeutics]].<ref>{{Cite web |last=Bianchini |first=Elisabetta |date=2020-11-10 |title=Acuitas Therapeutics: The Canadian technology that the Pfizer and BioNTech COVID-19 vaccine 'can't work without' |url=https://ca.news.yahoo.com/covid19-vaccine-coronavirus-canada-acuitas-therapeutics-pfizer-biontech-211410040.html |url-status=live |archive-url=https://web.archive.org/web/20220930214712/https://ca.news.yahoo.com/covid19-vaccine-coronavirus-canada-acuitas-therapeutics-pfizer-biontech-211410040.html |archive-date=2022-09-30 |access-date=2022-09-30 |website=[[Yahoo! News]] -CA}}</ref> Vaccines were injected into the first human participants in the U.S. in early May. In July 2020, Pfizer and BioNTech announced that two of the partners' four [[Messenger RNA|mRNA]] vaccine candidates had won fast track designation from the [[Food and Drug Administration|FDA]].<ref>{{Cite web |last=DeArment |first=Alaric |date=2020-07-13 |title=Pfizer, BioNTech get fast-track from FDA for Covid-19 vaccines |url=https://medcitynews.com/2020/07/pfizer-biontech-get-fast-track-from-fda-for-covid-19-vaccines/ |access-date=2020-07-15 |website=MedCity News}}</ref> The company began Phase{{spaces}}II-III testing on 30,000 people in the last week of July 2020 and was slated to be paid $1.95{{spaces}}billion for 100{{nbsp}}million doses of the vaccine by the US government.<ref>{{Cite news |title=Pfizer Beats Forecasts as Vaccine Trial Enters Final Stage |url=https://www.wsj.com/articles/pfizer-sales-fall-as-company-races-toward-covid-19-vaccine-11595936314 |website=The Wall Street Journal |date=July 29, 2020}}</ref> In September 2020, Pfizer and BioNTech announced that they had completed talks with the European Commission to provide an initial 200{{nbsp}}million vaccine doses to the EU, with the option to supply another 100{{nbsp}}million doses at a later date.<ref>{{Cite news |last=Kilgore |first=Tomi |title=Pfizer, BioNTech conclude talks over supplying EU with SARS-CoV-2 vaccine candidate |url=https://www.marketwatch.com/story/pfizer-biontech-conclude-talks-over-supplying-eu-with-sars-cov-2-vaccine-candidate-2020-09-09 |access-date=2020-09-10 |website=MarketWatch}}</ref>

On November 9, 2020, Pfizer announced that BioNTech's COVID-19 vaccine, tested on 43,500 people, was found to be 90% effective at preventing symptomatic COVID-19.<ref>{{Cite news |date=November 9, 2020 |title=Covid vaccine: First 'milestone' vaccine offers 90% protection |work=[[BBC News]] |url=https://www.bbc.com/news/health-54873105}}</ref> The efficacy was updated to 95% a week later, described as a "really a spectacular number" and made Pfizer and BioNTech the first companies to develop and test a working vaccine for COVID-19.<ref>{{Cite news |last1=Thomas |first1=Katie |last2=Gelles |first2=David |last3=Zimmer |first3=Carl |date=2020-11-09 |title=Pfizer's Early Data Shows Vaccine Is More Than 90% Effective |work=The New York Times |url=https://www.nytimes.com/2020/11/09/health/covid-vaccine-pfizer.html |access-date=2021-05-18 |issn=0362-4331}}</ref><ref name=":1">{{Cite web |last=Kounang |first=Nadia |date=9 November 2020 |title=Pfizer and BioNTech say final analysis shows coronavirus vaccine is 95% effective with no safety concerns |url=https://www.cnn.com/2020/11/18/health/pfizer-coronavirus-vaccine-safety/index.html |access-date=9 November 2020 |website=CNN}}</ref>

In November and December 2020, regulators in various countries approved Pfizer's vaccine for emergency use.<ref>{{Cite news | url=https://www.aljazeera.com/news/2020/12/24/vaccine-rollout-which-countries-have-started | title=Which countries have rolled out COVID vaccine? | work=[[Al Jazeera English]] | date=December 24, 2020}}</ref>

==== Development of oral antivirals ====
In November 2021, Pfizer launched a new COVID-19 oral antivirus treatment known as [[Nirmatrelvir/ritonavir|Paxlovid]]. In January 2022, the Pfizer CEO [[Albert Bourla]] confirmed that the trial results of a fourth dose were pending until March 2022. He said that the firm was setting up a collaboration to develop an anti-COVID pill treatment along with a French company, [[Novasep]]. He also said the COVID vaccine was "safe and efficient" for children.<ref>{{Cite web |url=https://www.israelnationalnews.com/news/320624 |title=Pfizer CEO: Current wave will be last with so many restrictions |access-date=17 January 2021 |website=[[Israel National News]]}}</ref><ref>{{Cite web |url=https://www.livemint.com/companies/news/pfizer-ceo-shares-some-good-news-on-covid-but-cautions-virus-could-circulate-for-years-11642405004050.html |title=Pfizer CEO shares some good news on covid but cautions virus could circulate for years |access-date=17 January 2021 |website=[[Mint (newspaper)|Mint]]}}</ref> In May 2022, reports emerged of patients experiencing "rebound" symptoms after completing a five-day course of Paxlovid.<ref>{{Cite news |last=Hopkins |first=Jared S. |date=2022-05-10 |title=Some Covid-19 Patients Relapse After Taking Paxlovid, Puzzling Doctors |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/some-covid-19-patients-relapse-after-taking-paxlovid-puzzling-doctors-11652186194 |access-date=2022-05-16 |issn=0099-9660}}</ref> The FDA responded by announcing they had performed additional analyses of the drug's clinical trial data, and decided against changing its recommendations.<ref>{{Cite journal |last=Farley |first=John |date=2022-05-04 |title=FDA Updates on Paxlovid for Health Care Providers |url=https://www.fda.gov/drugs/news-events-human-drugs/fda-updates-paxlovid-health-care-providers |archive-url=https://web.archive.org/web/20220504171821/https://www.fda.gov/drugs/news-events-human-drugs/fda-updates-paxlovid-health-care-providers |archive-date=May 4, 2022 |journal=[[Food and Drug Administration]] }}</ref> U.S. President [[Joe Biden]] and Dr. [[Anthony Fauci]] were both reported to experience this rebound syndrome in the months that followed, while continuing to recommend the drug for those who may benefit from it.<ref>{{Cite web |last=Samuels |first=Fionna M. D. |date=2022-08-08 |title=What Is Paxlovid Rebound, and How Common Is It? |url=https://www.scientificamerican.com/article/what-is-paxlovid-rebound-and-how-common-is-it/ |url-status=live |archive-url=https://archive.today/20220818063840/https://www.scientificamerican.com/article/what-is-paxlovid-rebound-and-how-common-is-it/ |archive-date=2022-08-18 |access-date=2022-08-22 |website=[[Scientific American]] }}</ref>

==== Corporate developments and acquisitions ====
In September 2020, the company acquired a 9.9% stake in CStone Pharmaceuticals for $200{{nbsp}}million (HK$1.55{{nbsp}}billion), helping to commercialise its anti-[[PD-L1]] monoclonal antibody, CS1001.<ref>{{Cite news |title=Pfizer to buy 9.9% of CStone for $200 million, eyes collaboration |url=https://www.reuters.com/article/us-cstone-pfizer/pfizer-to-buy-9-9-of-cstone-for-200-million-eyes-collaboration-idUKKBN26L01D |work=[[Reuters]] |date=September 29, 2020}}</ref> In October 2020, the company acquired Arixa Pharmaceuticals.<ref>{{Cite magazine |url=https://www.fiercebiotech.com/biotech/pfizer-snaps-up-antibiotics-maker-arixa-and-its-oral-avycaz-follow-up |title=Biotech Pfizer snaps up antibiotics maker Arixa and its oral Avycaz follow-up |first=Amirah |last=Al Idrus |magazine=Fierce Pharma | publisher=[[Questex]] |date=October 22, 2020}}</ref> In November 2020, using a [[Reverse Morris Trust]] structure, Pfizer merged its off-patent branded and [[generic drug]] business, known as Upjohn, with [[Mylan]] to form [[Viatris]], owned 57% by Pfizer shareholders.<ref>{{Cite news |url=https://www.nasdaq.com/articles/pfizer-completes-combination-of-upjohn-and-mylan-viatris-to-begin-trading-on-nov.-17-2020 |title=Pfizer Completes Combination Of Upjohn And Mylan; Viatris To Begin Trading On Nov. 17 |work=[[Nasdaq]] |date=November 16, 2020}}</ref><ref>{{Cite news |url=https://www.post-gazette.com/business/healthcare-business/2020/11/16/Mylan-merger-Upjohn-Viatris-bresch-coury-Pfizer-cost-cuts-generic-drugs/stories/202011160111 |title=Mylan completes merger with Upjohn to form Viatris |first=Patricia |last=Sabatini |work=[[Pittsburgh Post-Gazette]] |date=November 16, 2020}}</ref>

On January 5, 2021, Pfizer introduced a new [[logo]].<ref>{{Cite news |last=Bruell |first=Alexandra |title=Pfizer Introduces New Logo Playing Up Role in Drug Creation |url=https://www.wsj.com/articles/pfizer-introduces-new-logo-playing-up-role-in-drug-creation-11609844400 |work=[[The Wall Street Journal]] |date=January 5, 2021 |issn=0099-9660 |url-access=subscription}}</ref> In April 2021, Pfizer acquired Amplyx Pharmaceuticals and its anti-fungal compound [[fosmanogepix]] (APX001).<ref>{{cite magazine |url=https://www.fiercebiotech.com/biotech/pfizer-buys-amplyx-to-grow-infectious-disease-pipeline |title=Pfizer buys Amplyx to grow infectious disease pipeline |first=Nick Paul |last=Taylor |magazine=Fierce Pharma | publisher=[[Questex]] |date=April 28, 2021}}</ref><ref>{{Cite news |url=https://www.sandiegouniontribune.com/2021/04/28/pfizer-acquires-fungus-fighting-san-diego-biotech |title=Pfizer acquires fungus-fighting San Diego biotech |first=Jonathan |last=Wosen |work=[[The San Diego Union-Tribune]] |date=April 28, 2021}}</ref> In August, the company announced it would acquire Trillium Therapeutics Inc and its immuno-oncology portfolio for $2.3 billion.<ref>{{Cite news |url=https://www.reuters.com/business/pfizer-buy-trillium-therapeutics-226-bln-deal-2021-08-23/ |title=Pfizer to buy cancer drug developer Trillium in $2.3 BLN deal |newspaper=Reuters |date=August 23, 2021}}</ref><ref>{{Cite web |url=https://www.biospace.com/article/releases/pfizer-to-acquire-trillium-therapeutics-inc-/?s=79 |title=Pfizer to Acquire Trillium Therapeutics Inc|date=August 23, 2021 }}</ref>

In March 2022, the company acquired [[Arena Pharmaceuticals]] for $6.7 billion in cash.<ref>{{Cite press release | url=https://www.businesswire.com/news/home/20220310005794/en/Pfizer-Completes-Acquisition-of-Arena-Pharmaceuticals | title=Pfizer Completes Acquisition of Arena Pharmaceuticals | publisher=[[Business Wire]] | date=March 11, 2022}}</ref><ref>{{cite web |title=Pfizer bets on Arena's promising bowel disease treatment in $6.7 bln deal |url=https://www.reuters.com/markets/deals/pfizer-acquire-arena-pharmaceuticals-67-bln-deal-2021-12-13 |work=[[Reuters]] |date=December 13, 2021 |access-date=December 13, 2021}}</ref><ref>{{cite web |title=Pfizer to Acquire Arena Pharmaceuticals in $6.7 Billion Deal |url=https://www.wsj.com/articles/pfizer-to-acquire-arena-pharmaceuticals-in-6-7-billion-deal-11639414813 |work=[[The Wall Street Journal]] |last=Walker |first=Joseph |date=December 13, 2021 |access-date=December 13, 2021}}</ref> In June 2022, the company acquired ReViral Ltd, for up to $525 million, gaining access to experimental drugs used to combat [[respiratory syncytial virus]] infections.<ref>{{Cite news | url=https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-buy-rsv-drug-developer-reviral-up-525-mln-2022-04-07/ | title=Pfizer boosts respiratory drug portfolio with ReViral purchase | newspaper=Reuters | date=April 7, 2022 | last1=Satija | first1=Bhanvi }}</ref><ref>{{Cite web |date=2022-06-10 |title=Pfizer acquires biopharma firm ReViral for up to $525m |url=https://www.pharmaceutical-technology.com/news/pfizer-acquires-biopharma-reviral/ |access-date=2022-06-10 |website=Pharmaceutical Technology }}</ref> In October 2022, the company acquired Biohaven Pharma and its [[calcitonin gene-related peptide]] programs for $11.6 billion.<ref>{{cite web | url=https://www.biospace.com/article/releases/pfizer-completes-acquisition-of-biohaven-pharmaceuticals/?s=110 | title=Pfizer Completes Acquisition of Biohaven Pharmaceuticals | date=October 3, 2022 }}</ref><ref>{{cite press release | url=https://www.businesswire.com/news/home/20220510005676/en/Pfizer-to-Acquire-Biohaven-Pharmaceuticals | title=Pfizer to Acquire Biohaven Pharmaceuticals | date=May 10, 2022}}</ref><ref>{{cite web | url=https://www.biospace.com/article/pfizer-drops-a-cool-11-6-billion-on-migraine-leader-biohaven-/?s=79 | title=Pfizer Drops a Cool $11.6B on Migraine Leader Biohaven | date=May 10, 2022 }}</ref> It also acquired Global Blood Therapeutics for $5.4 billion, boosting Pfizer's rare disease business.<ref>{{Cite press release | url=https://www.businesswire.com/news/home/20221004006158/en/Pfizer-Completes-Acquisition-of-Global-Blood-Therapeutics | title=Pfizer Completes Acquisition of Global Blood Therapeutics | publisher=[[Business Wire]] | date=October 5, 2022}}</ref><ref>{{Cite news |last=Rockoff |first=Jonathan D. |date=2022-08-08 |title=Pfizer Agrees to $5.4 Billion Deal for Global Blood Therapeutics |work=[[The Wall Street Journal]] |url=https://www.wsj.com/articles/pfizer-reaches-5-4-billion-deal-for-global-blood-therapeutics-11659954601 |access-date=2022-08-08 |issn=0099-9660}}</ref><ref>{{Cite news |date=2022-08-08 |author-first1=Mrinalika|author-last1=Roy|author-first2=Michael|author-last2=Erman|title=Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 billion deal |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-buy-global-blood-therapeutics-54-bln-deal-2022-08-08/ |access-date=2022-08-08}}</ref>

In April 2023, Pfizer moved its world headquarters from [[42nd Street (Manhattan)|42nd Street]] in [[Midtown Manhattan]] to the Spiral at [[Hudson Yards (development)|Hudson Yards]].<ref>{{cite news |url=https://www.crainsnewyork.com/health-care/pfizer-opens-global-headquarters-hudson-yards-empty-offices-reach-pandemic-levels |last1=D'Ambrosio |first1=Amanda |title=Pfizer opens global headquarters in Hudson Yards as empty offices reach pandemic levels |work=[[Crain Communications]] |date=April 3, 2023}}</ref><ref>{{cite magazine |url=https://www.fiercepharma.com/pharma/pfizer-moves-west-side-settling-down-swanky-new-digs-hudson-yards-spiral-skyscraper |last1=Liu |first1=Angus |last2=Kansteiner |first2=Fraiser |title=Pfizer moves on up to the West Side, establishing new nerve center at Hudson Yards' Spiral skyscraper |magazine=Fierce Pharma | publisher=[[Questex]] |date=April 4, 2023}}</ref>

In December 2023, the company acquired [[Seagen]], a pioneer of [[antibody–drug conjugate]]s for the treatment of cancer, for $43{{nbsp}}billion.<ref>{{cite news |last=Mishra |first=Manas |date=2022-03-13 |title=Pfizer signs $43 bln Seagen deal in cancer drug push |url=https://www.reuters.com/markets/deals/pfizer-buy-seagen-deal-valued-43-billion-2023-03-13/ |publisher=[[Reuters]]}}</ref><ref>{{Cite press release | url=https://www.businesswire.com/news/home/20231213759493/en/Pfizer-Completes-Acquisition-of-Seagen | title=Pfizer Completes Acquisition of Seagen | publisher=[[Business Wire]] | date=December 14, 2023}}</ref>

In March 2025, the company sold its entire stake in Haleon for $3.24 billion to institutional investors.<ref>{{Cite news | url=https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-sells-entire-haleon-stake-324-billion-2025-03-19/ | title=Pfizer sells entire Haleon stake for $3.24 billion | first=Anandita | last=Mehrotra | editor-first=Mrigank | editor-last=Dhaniwala | work=[[Reuters]] | date=March 19, 2025}}</ref>

=== Partnership with Flagship Pioneering === 
In July 2024, Pfizer and Flagship Pioneering announced an "Innovation Supply Chain" partnership to co-develop 10 drug candidates. Each party committed $50 million upfront, leveraging Flagship's ecosystem of over 40 startups to align with Pfizer's priorities. Pfizer will fund the selected programs and has the option to license or acquire assets, with potential success milestones and royalties reaching up to $700 million per commercialized drug. Two programs, focused on [[obesity]] and [[Cardiovascular disease|cardiovascular diseases]], have already been initiated.<ref name=FBT>{{cite web |url=https://www.fiercebiotech.com/biotech/pfizer-flagship-return-obesity-part-latest-additions-multibillion-dollar-collaboration |title=Pfizer, Flagship return to obesity as part of latest additions to multibillion-dollar collaboration |author=James Waldron |website=Fierce Biotech | publisher=[[Questex]] |date=20 November 2024 |access-date=16 March 2025}}</ref>

The partnership represents a new model in pharmaceutical R&D, focusing on early collaboration with startups to streamline drug development. For startups, the model provides an opportunity for early engagement with pharmaceutical companies, offering potential funding and reduced uncertainty in development programs.<ref name=FBT/>

=== Collaboration with Ignition AI Accelerator === 
In October 2024, Pfizer announced a partnership with the Ignition AI Accelerator, a collaborative initiative by [[Nvidia|NVIDIA]], Tribe, and Digital Industry Singapore (DISG). The collaboration aims using [[artificial intelligence]] to expedite [[drug discovery]] and development processes, improve operational efficiency, and streamline stakeholder engagement. The initiative also focuses on optimizing manufacturing processes, including improving yields and reducing cycle times.<ref>{{cite web |title=Pfizer partners with Ignition AI to enhance drug discovery |url=https://itbrief.asia/story/pfizer-partners-with-ignition-ai-to-enhance-drug-discovery|author=Kaleah Salmon|date=14 October 2024 |website=IT Brief |access-date=5 April 2025}}</ref><ref>{{cite web |title=Singapore's Ignition AI Accelerator partners Pfizer to advance biopharma sector with AI |url=https://technode.global/2024/10/09/singapores-ignition-ai-accelerator-partners-pfizer-to-advance-biopharma-sector-with-ai/ |website=TNGlobal |date=9 October 2024 |access-date=5 April 2025}}</ref>

=== Expanding AI Collaboration for Clinical Trials with Saama === 
Saama and Pfizer reached an expanded multi-year agreement to integrate AI-driven solutions across Pfizer's R&D portfolio, building on their 2020 partnership. Initially the partnership focused on automating data review processes with the Smart Data Quality (SDQ) platform — developed during Pfizer's COVID-19 vaccine trials — the partnership as of 2024 scales to streamline data review and accelerate regulatory submissions across global studies. The expanded collaboration introduces Saama's Biometrics Research and Analysis Information Network, enabling faster statistical programming, biostatistics workflows, and submission-ready outputs.<ref>{{Cite news |title=Saama and Pfizer Expand Agreement to Integrate AI-Driven Data Solutions Across R&D Portfolio |url=https://www.businesswire.com/news/home/20240212789592/en/Saama-and-Pfizer-Expand-Agreement-to-Integrate-AI-Driven-Data-Solutions-Across-RD-Portfolio |archive-url=https://web.archive.org/web/20241024202742/https://www.businesswire.com/news/home/20240212789592/en/Saama-and-Pfizer-Expand-Agreement-to-Integrate-AI-Driven-Data-Solutions-Across-RD-Portfolio |archive-date=October 24, 2024 |access-date=2025-04-07 |date=2024-02-12 |url-status=live }}</ref>

== Acquisitions ==
{{Hidden begin|border=1px #aaa solid|title=Pfizer acquisitions|ta1=center}}
{{Tree list}}
* Pfizer {{small|(Founded 1849 as Charles Pfizer & Company)}}
** [[Warner–Lambert]] {{small|(Acq 2000)}}
*** William R. Warner {{small|(Founded 1856, merged 1955)}}
*** Lambert Pharmacal Company {{small|(Merged 1955)}}
*** Parke-Davis {{small|(Founded 1860, Acq 1976)}}
*** [[Wilkinson Sword]] {{small|(Acq 1993, divested 2003)}}
*** Agouron {{small|(Acq 1999)}}
** [[Pharmacia]] {{small|(Acq 2002)}}
*** [[Pharmacia & Upjohn]] {{small|(Merged 2000)}}
**** [[Pharmacia]] {{small|(Merged 1995)}}
***** Farmitalia Carlo Erba
***** Kabi Pharmacia
***** Pharmacia Aktiebolaget
**** [[The Upjohn Company]] {{small|(Merged 1995)}}
**** [[Monsanto]] {{small|(Merged 2000, divested 2002)}}
**** [[G.D. Searle, LLC|Searle]] {{small|(Merged 2000)}}
** Esperion Therapeutics {{small|(Acq 2003, divested 2008)}}
** Meridica {{small|(Acq 2004)}}
** Vicuron Pharmaceuticals {{small|(Acq 2005)}}
** Idun {{small|(Acq 2005)}}
** Angiosyn {{small|(Acq 2005)}}
** Powermed {{small|(Acq 2006)}}
** Rinat {{small|(Acq 2006)}}
** Coley Pharmaceutical Group {{small|(Acq 2007)}}
** CovX {{small|(Acq 2007)}}
** Encysive Pharmaceuticals Inc {{small|(Acq 2008)}}
** [[Wyeth]] {{small|(Acq 2009)}}
*** [[Chef Boyardee]] {{small|(Acq 1946, divested 1996 with food div)}}	
*** S.M.A. Corporation
*** Ayerst Laboratories {{small|(Acq 1943)}}
*** Fort Dodge Serum Company {{small|(Acq 1945)}}
*** [[Bristol-Myers]] {{small|(Animal Health div)}}
*** [[Parke-Davis]] {{small|(Animal Health div)}}
*** A.H. Robins
*** Sherwood Medical {{small|(Acq 1982)}}
*** [[Genetics Institute, Inc.]] {{small|(Acq 1992)}}
*** [[American Cyanamid]] {{small|(Acq 1994)}}
*** Lederle Laboratories
*** [[Solvay S.A.|Solvay]] {{small|(Acq 1995, Animal Health div)}}
** [[King Pharmaceuticals]] {{small|(Acq 2010)}}
*** Monarch Pharmaceuticals, Inc.
*** King Pharmaceuticals Research and Development, Inc.	
*** Meridian Medical Technologies, Inc.
*** Parkedale Pharmaceuticals, Inc.
*** King Pharmaceuticals Canada Inc.
*** Monarch Pharmaceuticals Ireland Limited
** Synbiotics Corporation {{small|(Acq 2011)}}
** Icagen {{small|(Acq 2011)}}
** Ferrosan {{small|(Consumer Health div, Acq 2011)}}
** Excaliard Pharmaceuticals {{small|(Acq 2011)}}
** Alacer Corp {{small|(Acq 2012)}}
** NextWave Pharmaceuticals, Inc {{small|(Acq 2012)}}
** Innopharma {{small|(Acq 2014)}}
** Redvax GmbH {{small|(Acq 2014)}}
** Hospira {{small|(Spun off from Abbott Laboratories 2004, Acq 2015)}}	
*** Mayne Pharma Ltd {{small|(Acq 2007)}}
*** Pliva-Croatia	
*** [[Orchid Chemicals & Pharmaceuticals Ltd.]] {{small|(Generics & Injectables div, Acq 2009)}}	
*** Javelin Pharmaceuticals, Inc. {{small|(Acq 2010)}}	
*** TheraDoc {{small|(Acq 2010)}}
*** Arixa Pharmaceuticals {{small|(Acq 2020)}}
** Anacor Pharmaceuticals{{small|(Acq 2016)}}
** Bamboo Therapeutics {{small|(Acq 2016)}}
** [[Medivation]] {{small|(Acq 2016)}}
** [[AstraZeneca]] {{small|(Small molecule antibiotic div, Acq 2016)}}
** [[Array BioPharma]] {{small|(Acq 2019)}}
** Amplyx Pharmaceuticals {{small|(Acq 2021)}}
** Trillium Therapeutics {{small|(Acq 2021)}}
** [[Arena Pharmaceuticals]] {{small|(Acq 2022)}}
** ReViral Ltd {{small|(Acq 2022)}}
** Biohaven Pharma {{small|(Acq 2022)}}
*** Kleo Pharmaceuticals, Inc. {{small|(Acq 2021)}}
** [[Seagen]] {{small|(Acq 2023)}}
*** Cascadian Therapeutics {{small|(Acq 2018)}}
{{Tree list/end}}
{{Hidden end}}

==Areas of focus==
Pfizer focuses on addressing critical health challenges through innovation in various therapeutic areas. In the field of rare diseases, the company develops treatments for conditions such as [[Duchenne muscular dystrophy]], [[Haemophilia|hemophilia]], [[sickle cell disease]], and [[Gaucher's disease|Gaucher disease]], with an inclination on [[gene therapy]] and improving diagnostic resources for patients with unmet medical needs.<ref>{{cite web |title=Pfizer gene therapy research delayed by trial changes, safety questions |author=Ned Pagliarulo|url=https://www.biopharmadive.com/news/pfizer-gene-therapy-delay-dmd-hemophilia/609390/ |date=3 November 2021|website=BioPharma Dive |access-date=26 March 2025}}</ref>

===Internal medicine===
Pfizer has a longstanding history in vaccines, contributing to breakthroughs in diseases like polio and smallpox. Currently, the company focuses on vaccines for pneumococcal and meningococcal diseases, influenza, respiratory syncytial virus (RSV), [[Lyme disease]], and [[Clostridioides difficile]].<ref>{{cite web |title=Pfizer reports durable second-season efficacy for RSV vaccine |author=Lisa Schnirring|date=29 February 2024 |url=https://www.cidrap.umn.edu/respiratory-syncytial-virus-rsv/pfizer-reports-durable-second-season-efficacy-rsv-vaccine |website=[[Center for Infectious Disease Research & Policy]] |access-date=27 March 2025}}</ref><ref>{{cite web |title=Lyme Disease Vaccine Reaches Completion of the Primary Series
|url=https://www.contagionlive.com/view/lyme-disease-vaccine-reaches-completion-of-the-primary-series |author=John Parkinson|date=19 July 2024|website=Contagion |access-date=27 March 2025}}</ref> It also invests in maternal and neonatal vaccines, [[cancer prevention]], and efforts to mitigate [[Hospital-acquired infection|hospital-acquired infections]]. It also works in advancing therapies for issues related to metabolic and cardiovascular health, including obesity, [[type 2 diabetes]], [[insulin resistance]], and non-alcoholic fatty liver disease (NAFLD).<ref>{{cite web |title=CDC Endorses Pfizer's Maternal RSV Vaccine to Shield Newborns |url=https://respiratory-therapy.com/products-treatment/pharmaceuticals/us-pharmaceuticals/cdc-endorses-pfizers-maternal-rsv-vaccine-shield-newborns/ |website=Respiratory Therapy|date=26 September 2023|access-date=27 March 2025}}</ref>

===Obesity treatment developments=== 
Pfizer has advanced its obesity treatment research through the development of [[danuglipron]], an oral [[glucagon-like peptide-1]] (GLP-1) receptor agonist:<ref name="techtarget">{{cite web |title=Pfizer advances daily oral GLP-1 research |url=https://www.techtarget.com/pharmalifesciences/news/366606009/Pfizer-advances-daily-oral-GLP-1-research|author=Veronica Salib |website=TechTarget |date=12 July 2024|access-date=29 March 2025}}</ref>

* '''Danuglipron Development''': Initial trials of the twice-daily formulation showed potential for weight loss and blood sugar management. 

* '''New Formulation''': A once-daily modified-release version has been identified for further study, showing a suitable pharmacokinetic profile and no significant safety issues in trials involving 1,400 participants.

Dose optimization trials are planned for late 2024 to support large-scale registration studies.<ref name="techtarget"/>

In November 2025, Pfizer agreed to acquire Metsera to expand its weight-loss drug portfolio in a deal that had the potential to exceed $10 billion.<ref>{{Cite web |last=Rockoff |first=Jonathan D. |date=2025-11-08 |title=Pfizer and Metsera Reach Deal Expected to Top $10 Billion |url=https://www.wsj.com/health/pharma/pfizer-and-metsera-reach-deal-worth-up-to-10-billion-be5def52 |access-date=2025-11-11 |website=The Wall Street Journal |language=en-US}}</ref> 

===Oncology=== 
Pfizer develops targeted therapies to treat multiple cancer types, including bladder, breast, cervical, lung, and colorectal cancers, as well as hematological malignancies. The company conducts research on [[Personalized medicine|precision medicine]] and [[immunotherapy]], aiming to improve survival rates and quality of life for cancer patients. Specially, the acquisition of Seagen has supported further development of oncology treatments, including mRNA cancer vaccines.<ref name="Driving equitable">{{cite web |title=Elif Aral: Driving equitable healthcare in the region |url=https://www.arabianbusiness.com/resources/elif-aral-driving-equitable-healthcare-in-the-region |date=22 October 2024|website=[[Arabian Business]] |access-date=30 March 2025}}</ref>

* '''Prostate Cancer''': The EMBARK trial showed improved metastasis-free survival in high-risk, non-metastatic prostate cancer patients, leading to the FDA approval of a combination therapy in 2023.<ref>{{cite journal |title=Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer |author=Stephen J. Freedland, M.D., Murilo de Almeida Luz, M.D., Ugo De Giorgi, M.D., Ph.D., Martin Gleave, M.D., Geoffrey T. Gotto, M.D., M.P.H., Christopher M. Pieczonka, M.D., Gabriel P. Haas, M.D., Choung-Soo Kim, M.D., Miguel Ramirez-Backhaus, M.D., Antti Rannikko, M.D., Ph.D., Jamal Tarazi, M.D., M.P.A., Swetha Sridharan, M.B., B.S., Jennifer Sugg, M.S., Yiyun Tang, Ph.D., Ronald F. Tutrone, Jr., M.D., Balaji Venugopal, M.B., B.S., M.D., Arnauld Villers, M.D., Ph.D., Henry H. Woo, M.B., B.S., D.Med.Sc., Fabian Zohren, M.D., Ph.D., and Neal D. Shore, M.D. |url=https://www.nejm.org/doi/full/10.1056/NEJMoa2303974 |journal=[[The New England Journal of Medicine]] |date=2023-10-18 |volume=389 |issue=16 |pages=1453–1465 |access-date=2025-03-30 |doi=10.1056/NEJMoa2303974|pmid=37851874 |url-access=subscription }}</ref>

* '''The TALAPRO-2''' study explored treatments for metastatic prostate cancer with homologous recombination repair mutations, which are found in 25% of cases.<ref>{{cite web |title=Clinical Trials + Font Resize - Pfizer announces positive results from phase 3 TALAPRO-2 trial of Talzenna in combination with Xtandi in patients with mCRPC |url=https://www.pharmabiz.com/NewsDetails.aspx?aid=172947&sid=2 |website=Pharmabiz.com |date=11 October 2024|access-date=30 March 2025}}</ref>

* '''Bladder Cancer:''' The EV-302 study investigated new treatments for advanced urothelial cancer, focusing on improving care for hard-to-treat patient groups.<ref>{{cite web |title=PADCEV® (Enfortumab Vedotin-ejfv) with KEYTRUDA® (Pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer |url=https://www.urotoday.com/ev-302-te/articles.html?id=148585 |website=UroToday |access-date=30 March 2025}}</ref>

===Advances in AI, gene therapy, and breakthrough treatments=== 
Pfizer has also started initiatives which aim to address healthcare challenges across various regions and therapeutic areas in advancements in artificial intelligence (AI), gene therapy, obesity treatments, and oncology research. In 2023, Pfizer's affordability and access programs reached 45 million patients in the MERA region, supported by the IUdo app, which was launched in [[Egypt]], [[Qatar]], and [[Lebanon]] to facilitate patient access to care. In 2024, Pfizer focuses on integrating AI and gene therapy in the [[Middle East]], [[Russia]], and [[Africa]] (MERA) region, with its headquarters in [[Dubai]].<ref name="Driving equitable"/> Key initiatives include:
* '''Personalized Healthcare''': Omnichannel strategies are being used to provide tailored healthcare solutions for patients and professionals.<ref>{{cite web |title=Omnichannel Engagement in Pharma: Process and Challenges |url=https://medicaldigitals.com/blogs/pharmaceutical-marketing/omnichannel-engagement-pharma/ |date=24 January 2024|website=Medical Digitals |access-date=6 April 2025}}</ref>
* '''AI-Powered Education Programs:''' AI-driven atrial fibrillation programs localized educational materials into multiple languages, increasing accessibility. 
* '''Rare Disease Research:''' Collaboration with the Abu Dhabi Department of Health to analyze real-world data on Sickle Cell Disease using AI.<ref>{{cite web |title=Department of Health – Abu Dhabi Partners with Pfizer to Advance Research in Sickle Cell Disease and Beyond |url=https://www.doh.gov.ae/en/news/doh-partners-with-pfizer-to-advance-research-in-sickle-cell-disease-and-beyond |website=Department of Health Abu Dhabi|date=4 June 2024|access-date=6 April 2025}}</ref>

==Legal issues==
===Aggressive pharmaceutical marketing===
{{See also|List of largest pharmaceutical settlements|Franklin v. Parke-Davis}}
Pfizer has been accused of aggressive [[pharmaceutical marketing]].<ref>{{Cite news |url=https://nymag.com/nymetro/health/features/3122/ |title=Inside the Happiness Business |last=Kirkpatrick |first=David D. |work=[[New York (magazine)|New York]] |date=May 15, 2000}}</ref><ref>{{Cite journal |last=Oldani |first=Michael |date=2002 |title=Tales from the Script |url=https://digitalassets.lib.berkeley.edu/anthpubs/ucb/text/kas087-006.pdf |journal=Kroeber Society Papers |volume=87 |pages=147–176 |via=University of California Berkeley}}</ref><ref>{{Cite journal |last=Oldani |first=Michael J. |date=2004 |title=Thick Prescriptions: Toward an Interpretation of Pharmaceutical Sales Practices |journal=Medical Anthropology Quarterly |volume=18 |issue=3 |pages=325–356 |doi=10.1525/maq.2004.18.3.325 |issn=1548-1387 |pmid=15484967}}</ref>

====Illegal marketing of gabapentin for off-label uses settlement (2004)====
In 1993, the [[Food and Drug Administration]] (FDA) approved [[gabapentin]] only for treatment of [[seizures]]. [[Warner–Lambert]], which merged with Pfizer in 2000, used [[continuing medical education]] and [[medical research]], sponsored articles about the drug for the medical literature, and alleged suppression of unfavorable study results, to promote gabapentin. Within five years, the drug was being widely used for [[off-label use]]s such as treatment of pain and psychiatric conditions. Warner–Lambert admitted to violating FDA regulations by promoting the drug for pain, psychiatric conditions, migraine, and other unapproved uses.<ref>{{Cite journal |vauthors=Steinman MA, Bero LA, Chren MM, Landefeld CS |date=August 2006 |title=Narrative review: the promotion of gabapentin: an analysis of internal industry documents |journal=[[Annals of Internal Medicine]] |volume=145 |issue=4 |pages=284–93 |doi=10.7326/0003-4819-145-4-200608150-00008 |pmid=16908919 |doi-access=free}}</ref> In 2004, the company paid $430{{nbsp}}million in one of the largest settlements to resolve criminal and civil health care liability charges. It was the first off-label promotion case successfully brought under the [[False Claims Act]].<ref>{{Cite journal |last=Henney JE |date=August 2006 |title=Safeguarding patient welfare: who's in charge? |journal=[[Annals of Internal Medicine]] |volume=145 |issue=4 |pages=305–7 |doi=10.7326/0003-4819-145-4-200608150-00013 |pmid=16908923 |s2cid=39262014}}</ref> A Cochrane review concluded that gabapentin is ineffective in migraine prophylaxis.<ref>{{Cite journal |vauthors=Mulleners WM, McCrory DC, Linde M |date=August 2014 |title=Antiepileptics in migraine prophylaxis: An updated Cochrane review |journal=Cephalalgia |volume=35 |issue=1 |pages=51–62 |doi=10.1177/0333102414534325 |pmid=25115844 |s2cid=43079346|doi-access=free }}</ref> The [[American Academy of Neurology]] rates it as having unproven efficacy, while the [[Canadian Headache Society]] and the [[European Federation of Neurological Societies]] rate its use as being supported by moderate and low-quality evidence.<ref>{{Cite journal |vauthors=Loder E, Burch R, Rizzoli P |date=June 2012 |title=The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines |journal=Headache |volume=52 |issue=6 |pages=930–45 |doi=10.1111/j.1526-4610.2012.02185.x |pmid=22671714 |doi-access=free |s2cid=540800}}</ref>

====Illegal marketing of Bextra settlement (2009)====
In September 2009, Pfizer pleaded guilty to the illegal marketing of [[arthritis]] drug [[valdecoxib]] (Bextra) and agreed to a $2.3{{nbsp}}billion settlement, the largest [[health care fraud]] settlement at that time.<ref>{{cite web |title=Justice Department Announces Largest Health Care Fraud Settlement in Its History |url=https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history |publisher=[[United States Department of Justice]] |access-date=2022-05-15 |archive-url=https://web.archive.org/web/20220512181155/https://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history |archive-date=May 12, 2022 |date=2009-09-09 |quote=American pharmaceutical giant Pfizer Inc. and its subsidiary Pharmacia & Upjohn Company Inc. (hereinafter together "Pfizer") have agreed to pay $2.3 billion, the largest health care fraud settlement in the history of the Department of Justice, to resolve criminal and civil liability arising from the illegal promotion of certain pharmaceutical products, the Justice Department announced today.}}</ref> Pfizer promoted the sale of the drug for several uses and dosages that the [[Food and Drug Administration]] specifically declined to approve due to safety concerns. The drug was pulled from the market in 2005.<ref>{{Cite news |url=https://www.nytimes.com/2009/09/03/business/03health.html |title=Pfizer pays $2.3 billion to settle marketing case |first=Gardiner |last=Harris |work=[[The New York Times]] |date=September 2, 2009 |url-access=limited}}</ref> It was Pfizer's fourth such settlement in a decade.<ref name=Settle/><ref name=Improper>{{Cite news |last=Johnson |first=Carrie |date=September 3, 2009 |title=In Settlement, A Warning To Drugmakers: Pfizer to Pay Record Penalty In Improper-Marketing Case |newspaper=[[The Washington Post]] |url=https://www.washingtonpost.com/wp-dyn/content/article/2009/09/02/AR2009090201449_pf.html}}</ref><ref name=fine/> The payment included $1.195{{nbsp}}billion in criminal penalties for felony violations of the [[Federal Food, Drug, and Cosmetic Act]], and $1.0{{nbsp}}billion to settle allegations it had illegally promoted the drugs for uses that were not approved by the [[Food and Drug Administration]] (FDA) leading to violations under the [[False Claims Act]] as reimbursements were requested from Federal and State programs. The criminal fine was the largest ever assessed in the United States to date.<ref name=Settle>{{Cite news |last=Harris |first=Gardiner |title=Pfizer Pays $2.3 billion to Settle Marketing Case |work=[[The New York Times]] |url=https://www.nytimes.com/2009/09/03/business/03health.html |date=September 3, 2009}}</ref><ref name=Improper/><ref name=fine>{{Cite news |title=Pfizer agrees record fraud fine |work=[[BBC News]] |url=http://news.bbc.co.uk/2/hi/business/8234533.stm |date=September 2, 2009}}</ref> Pfizer entered a [[corporate integrity agreement]] with the [[Office of Inspector General (United States)|Office of Inspector General]] that required it to make substantial structural reforms within the company, and publish to its website its post approval commitments and a searchable database of all payments to physicians made by the company.<ref>{{Cite web |title=Corporate Integrity Agreement between the Office of the Inspector General of the Department of Health and Human Services and Pfizer Inc. |url=https://oig.hhs.gov/fraud/cia/agreements/pfizer_inc.pdf |website=[[Office of Inspector General (United States)|Office of Inspector General]] |date=August 31, 2009 |url-status=live |archive-url=https://web.archive.org/web/20110715112330/http://oig.hhs.gov/fraud/cia/agreements/pfizer_inc.pdf |archive-date=July 15, 2011}}</ref>

====Termination of Peter Rost (2005)====
[[Peter Rost (doctor)|Peter Rost]] was vice president in charge of the [[endocrinology]] division at [[Pharmacia]] before its acquisition by Pfizer. During that time he raised concerns internally about [[kickback (bribery)|kickbacks]] and off-label marketing of Genotropin, Pharmacia's [[human growth hormone]] drug. Pfizer reported the Pharmacia marketing practices to the FDA and Department of Justice; Rost was unaware of this and filed an FCA lawsuit against Pfizer. Pfizer kept him employed, but isolated him until the FCA suit was unsealed in 2005. The Justice Department declined to intervene, and Pfizer fired him, and he filed a wrongful termination suit against Pfizer. Pfizer won a summary dismissal of the case, with the court ruling that the evidence showed Pfizer had decided to fire Rost prior to learning of his whistleblower activities.<ref>{{Cite web |title=ROST v. PFIZER, INC. |publisher=Casetext |url=https://casetext.com/case/rost-v-pfizer-2 |access-date=November 26, 2015 |archive-date=August 6, 2020 |archive-url=https://web.archive.org/web/20200806081254/https://casetext.com/case/rost-v-pfizer-2 }}</ref><ref>{{Cite news |url=https://www.nytimes.com/2005/06/08/business/at-pfizer-the-isolation-increases-for-a-whistleblower.html |title=At Pfizer, the Isolation Increases for a Whistle-Blower |first=Alex |last=Berenson |author-link=Alex Berenson |work=[[The New York Times]] |date=June 8, 2005 |url-access=limited}}</ref>

====Illegal marketing of Rapamune settlement (2014)====
A "whistleblower suit" was filed in 2005 against [[Wyeth]], which was acquired by Pfizer in 2009, alleging that the company illegally marketed [[sirolimus]] (Rapamune) for [[off-label use]]s, targeted specific doctors and medical facilities to increase sales of Rapamune, tried to get transplant patients to change from their transplant drugs to Rapamune, and specifically targeted [[African Americans]]. According to the whistleblowers, Wyeth also provided doctors and hospitals that prescribed the drug with kickbacks such as grants, donations, and other money.<ref>{{Cite magazine |url=https://www.fiercepharma.com/pharma/congress-joins-probe-into-wyeth-s-rapamune-marketing |title=Congress joins probe into Wyeth's Rapamune marketing |first=Tracy |last=Staton |magazine=Fierce Pharma | publisher=[[Questex]] |date=June 14, 2010}}</ref> In 2013, the company pleaded guilty to criminal mis-branding violations under the [[Federal Food, Drug, and Cosmetic Act]]. By August 2014, it had paid $491{{nbsp}}million in civil and criminal penalties related to Rapamune.<ref>{{Cite magazine |url=https://www.fiercepharma.com/regulatory/pfizer-settles-more-off-label-marketing-cases-tied-to-rapamune |title=Pfizer settles more off-label marketing cases tied to Rapamune |first=Eric |last=Palmer |magazine=Fierce Pharma | publisher=[[Questex]] |date=June 14, 2010}}</ref>

====Illegal marketing settlement (2014)====
In June 2010, health insurance network [[Blue Cross Blue Shield]] (BCBS) filed a lawsuit against Pfizer for allegedly illegally marketing drugs Bextra, Geodon and Lyrica. BCBS alleged that Pfizer used kickbacks and wrongly persuaded doctors to prescribe the drugs.<ref>{{Cite news |title=Blue Cross Names and Shames Pfizer Execs Linked to Massages-for-Prescriptions Push |url=https://www.cbsnews.com/news/blue-cross-names-and-shames-pfizer-execs-linked-to-massages-for-prescriptions-push/ |first=Jim |last=Edwards |work=[[CBS News]] |date=June 10, 2010}}</ref><ref>{{Cite news |url=https://www.bizjournals.com/austin/stories/2010/06/07/daily52.html |title=Blue Cross Blue Shield of Texas sues Pfizer |last=Bounds |first=Jeff |work=[[American City Business Journals]] |date=June 10, 2010}}</ref> According to the lawsuit, Pfizer handed out 'misleading' materials on [[off-label use]]s, sent over 5,000 doctors on trips to the [[Caribbean]] or around the United States, and paid them $2,000 honoraria in return for listening to lectures about Bextra.<ref>{{Cite magazine |url=https://www.fiercepharma.com/pharma/bcbs-names-pfizer-managers-kickback-suit |title=BCBS names Pfizer managers in kickback suit |magazine=Fierce Pharma | publisher=[[Questex]] |first=Tracy |last=Staton |date=June 11, 2010}}</ref><ref>{{Cite news |url=https://www.dallasnews.com/business/2010/06/11/blue-cross-blue-shield-of-texas-sues-pfizer-over-drug-marketing/ |title=Blue Cross Blue Shield of Texas sues Pfizer over drug marketing |work=[[The Dallas Morning News]] |date=June 11, 2010 |url-access=subscription}}</ref> Despite Pfizer's claims that "the company's intent was pure" in fostering a legal exchange of information among doctors, an internal marketing plan revealed that Pfizer intended to train physicians "to serve as public relations spokespeople."<ref name=toobig/> The case was settled in 2014 for $325{{nbsp}}million.<ref>{{Cite news |title=Pfizer Agrees to $325 Million Neurontin Marketing Accord |url=https://www.bloomberg.com/news/2014-06-02/pfizer-agrees-to-325-million-settlment-over-neurontin.html |first=Christie |last=Smythe |work=[[Bloomberg News]] |date=June 2, 2014 |url-access=subscription}}</ref> Fearing that Pfizer is "[[too big to fail]]" and that prosecuting the company would result in disruptions to [[Medicare (United States)|Medicare]] and [[Medicaid]], federal prosecutors instead charged a subsidiary of a subsidiary of a subsidiary of Pfizer, which is "nothing more than a shell company whose only function is to plead guilty."<ref name=toobig>{{cite news |url=https://edition.cnn.com/2010/HEALTH/04/02/pfizer.bextra/index.html |title=Feds found Pfizer too big to nail |last1=Griffin |first1=Drew |last2=Segal |first2=Andy |work=[[CNN]] |date=April 2, 2010}}</ref>

===Quigley Company asbestos settlement (2013)===
The Quigley Company, which sold [[asbestos]]-containing insulation products until the early 1970s, was acquired by Pfizer in 1968. In June 2013, asbestos victims and Pfizer negotiated a settlement that required Pfizer to pay a total of $964{{nbsp}}million: $430{{nbsp}}million to 80% of existing plaintiffs and place an additional $535{{nbsp}}million into a settlement trust that will compensate future plaintiffs as well as the remaining 20% of plaintiffs with claims against Pfizer and Quigley. Of that $535{{nbsp}}million, $405{{nbsp}}million is in a 40-year note from Pfizer, while $100{{nbsp}}million is from insurance policies.<ref>{{Cite news |url=https://www.theday.com/article/20130627/BIZ03/306279581 |title=Pfizer to pay $958M to end asbestos litigation |first=Tiffany |last=Kary |agency=[[Bloomberg News]] |date=June 27, 2013 |archive-date=May 1, 2021 |access-date=May 1, 2021 |archive-url=https://web.archive.org/web/20210501205526/https://www.theday.com/article/20130627/BIZ03/306279581 |url-status=dead }}</ref>

===Shiley defective heart valves settlement (1994)===
Pfizer purchased Shiley in 1979, at the onset of its Convexo-Concave valve ordeal, involving the [[Bjork–Shiley valve]]. Approximately 500 people died when defective [[heart valve]]s fractured and, in 1994, Pfizer agreed to pay $10.75{{nbsp}}million to settle claims by the [[United States Department of Justice]] that the company lied to get approval for the valves.<ref>{{Cite news |url=https://www.nytimes.com/1994/07/02/business/pfizer-unit-to-settle-charges-of-lying-about-heart-valve.html |title=Pfizer Unit to Settle Charges Of Lying About Heart Valve |first=Barry |last=Meier |work=The New York Times |author-link=Barry Meier |date=July 2, 1994 |url-access=limited}}</ref>

===Firing of employee that filed suit (2010)===
A federal lawsuit was filed by a scientist claiming she got an infection by a genetically modified [[lentivirus]] while working for Pfizer, resulting in intermittent [[paralysis]].<ref>{{Cite news |title=Ex-Pfizer Worker Cites Genetically Engineered Virus In Lawsuit Over Firing |url=https://www.courant.com/news/connecticut/hc-xpm-2010-03-14-hc-pfizer-virus-lawsuit-0314-artmar14-story.html |work=[[Hartford Courant]] |date=March 14, 2010 |url-status=live |archive-url=https://archive.today/20120728144301/http://www.courant.com/news/connecticut/hc-pfizer-virus-lawsuit-0314.artmar14,0,5614508,print.story |archive-date=July 28, 2012}}</ref> A judge dismissed the case citing a lack of evidence that the illness was caused by the virus but the jury ruled that by firing the employee, Pfizer violated laws protecting [[freedom of speech]] and [[whistleblower]]s and awarded her $1.37{{nbsp}}million.<ref>{{Cite news |title=A Pfizer Whistle-Blower Is Awarded $1.4 Million |url=https://www.nytimes.com/2010/04/03/business/03pfizer.html |first1=Andrew |last1=Pollack |first2=Duff |last2=Wilson |author-link2=Duff Wilson |work=[[The New York Times]] |date=April 2, 2010 |url-access=limited}}</ref>

===Celebrex intellectual property settlement (2012)===
[[Brigham Young University]] (BYU) said a professor of chemistry, Dr. [[Daniel L. Simmons]], discovered an enzyme in the 1990s that led towards development of [[Celebrex]]. BYU was originally seeking a 15% royalty on sales, equating to $9.7{{nbsp}}billion. A research agreement had been made between BYU and [[Monsanto]], whose pharmaceutical business was later acquired by Pfizer, to develop a better [[aspirin]]. The enzyme Dr. Simmons claims to have discovered would induce pain and inflammation while causing gastrointestinal problems and Celebrex is used to reduce those issues. A six-year battle ensued because BYU claimed that Pfizer did not give Dr. Simmons credit or compensation, while Pfizer claimed that it had met all obligations regarding the Monsanto agreement. In May 2012, Pfizer settled the allegations, agreeing to pay $450{{nbsp}}million.<ref>{{cite news |url=https://www.nytimes.com/2012/05/02/health/pfizer-settles-byu-lawsuit-over-development-of-celebrex.html |title=Pfizer Settles B.Y.U. Lawsuit Over Development of Celebrex |agency=[[Associated Press]] |work=[[The New York Times]] |date=May 1, 2012 |url-access=limited}}</ref>

===Nigeria Trovafloxacin lawsuit settlement (2011)===
{{main|Abdullahi v. Pfizer, Inc.}}

In 1996, an outbreak of measles, cholera, and bacterial meningitis occurred in Nigeria. Pfizer representatives and personnel from a contract research organization (CRO) traveled to [[Kano (city)|Kano]] to set up a clinical trial and administer an experimental [[antibiotic]], [[trovafloxacin]], to approximately 200 children.<ref>{{Citation |last=Oldani |first=Michael |title=The SAGE Encyclopedia of Pharmacology and Society |date=2016 |pages=1444–1447 |chapter=Trovafloxacin (Trovan) Controversy |chapter-url=http://sk.sagepub.com/reference/the-sage-encyclopedia-of-pharmacology-and-society/i11727.xml |publisher=SAGE Publications Inc. |doi=10.4135/9781483349985.n409 |isbn=978-1-4833-5000-4 |access-date=2019-01-21}}</ref> Tests in animals showed that Trovan had life-threatening side effects, including joint disease, abnormal cartilage growth, liver damage, and a degenerative bone condition. Pfizer's representatives did not alert the parents or patients about the serious risks involved, or tell them about an effective conventional treatment that Doctors without Borders was providing at the same site.<ref>{{cite web |title=Abdullahi v. Pfizer, Inc.- clinical trial |url=https://www.academia.edu/39569927 |access-date=30 January 2025 |website=academia.edu|date=January 2019 }}</ref> Local Kano officials reported that more than fifty children died in the experiment, while many others developed mental and physical deformities such as blindness, deafness, paralysis, and brain damage.<ref>{{Cite news |url=http://news.bbc.co.uk/2/hi/africa/6768799.stm |last=Murray |first=Senan |title=Anger at deadly Nigerian drug trials |work=[[BBC News]] |date=June 20, 2007}}</ref> The nature and frequency of both fatalities and other adverse outcomes were similar to those historically found among pediatric patients treated for meningitis in sub-Saharan Africa.<ref>{{Cite journal |vauthors=Ramakrishnan M, Ulland AJ, Steinhardt LC, Moïsi JC, Were F, Levine OS |year=2009 |title=Sequelae due to bacterial meningitis among African children: a systematic literature review |journal=[[BMC Medicine]] |volume=7 |article-number=47 |doi=10.1186/1741-7015-7-47 |pmc=2759956 |pmid=19751516 |doi-access=free }}</ref> In 2001, families of the children, as well as the governments of Kano and Nigeria, filed lawsuits regarding the treatment.<ref>{{Cite news |url=http://news.bbc.co.uk/2/hi/business/1517171.stm |title=Nigerians sue Pfizer over test deaths |work=[[BBC News]] |date=August 30, 2001}}</ref> According to ''[[Democracy Now!]]'', "[r]esearchers did not obtain signed consent forms, and medical personnel said Pfizer did not tell parents their children were getting the experimental drug."<ref name="DN">{{Cite news |url=https://www.democracynow.org/2010/12/17/wikileaks_cables_pfizer_targeted_nigerian_attorney |title=WikiLeaks Cables: Pfizer Targeted Nigerian Attorney General to Undermine Suit over Fatal Drug Tests |work=[[Democracy Now!]] |date=December 17, 2010}}</ref> The lawsuits also accused Pfizer of using the outbreak to perform unapproved human testing, as well as allegedly under-dosing a control group being treated with traditional antibiotics in order to skew the results of the trial in favor of Trovan. Nigerian medical personnel as well as at least one Pfizer physician said the trial was conducted without regulatory approval.<ref>{{Cite news |url=https://www.washingtonpost.com/wp-dyn/content/article/2006/05/06/AR2006050601338.html |title=Panel Faults Pfizer in '96 Clinical Trial In Nigeria |newspaper=[[The Washington Post]] |date=May 7, 2006}}</ref><ref>{{Cite news |url=https://www.cbsnews.com/news/pfizer-bribed-nigerian-officials-in-fatal-drug-trial-ex-employee-claims/ |title=Pfizer Bribed Nigerian Officials in Fatal Drug Trial, Ex-Employee Claims |first=Jim |last=Edwards |work=[[CBS News]] |date=February 10, 2011}}</ref>

In 2007, Pfizer published a Statement of Defense letter, claiming that Trozan was safely tested in five thousand patients prior to the Nigerian children clinical trial, and mortality in the patients treated by Pfizer was lower than that observed historically in African meningitis epidemics.<ref>{{Cite web |date=July 2007 |title=Trovan, Kano State Civil Case – Statement Of Defense |url=https://cdn.pfizer.com/pfizercom/news/trovan_statement_defense_summary.pdf |publisher=Pfizer}}</ref> They claim that the effects suffered by the victims were due to meningitis and not Trovan. Pfizer states that its actions did not violate any law, as there was no law in Nigeria that requires ethical committee approval prior to conducting a clinical trial. However, the drug was never tested in children before. Pfizier claims that no unusual side effects, unrelated to meningitis, were observed after four weeks in the Nigerian children clinical study, though an investigation by the Washington Post revealed that one of the children continued to have the drug administered to them until their death despite their condition worsening, which violated ethical guidelines.<ref>{{Cite web |date=July 2006 |title=Panel Faults Pfizer in '96 Clinical Trial In Nigeria|url=https://www.washingtonpost.com/archive/politics/2006/05/07/panel-faults-pfizer-in-96-clinical-trial-in-nigeria-span-classbankheadunapproved-drug-tested-on-childrenspan/73545064-6035-4715-8070-4c5a65e9a9cd/ |publisher=Washington Post}}</ref> 

In March 2001 the license for Trovan was withdrawn in Europe, by the European Commission due to liver toxicity and some deaths.<ref>{{Cite web |date=March 2001 |title=European commission decision on Trovan|url=https://www.ema.europa.eu/en/medicines/human/EPAR/trovan |publisher=European Commission}}</ref> 

In June 2010, the US Supreme Court rejected Pfizer's appeal against a ruling allowing lawsuits by the Nigerian families to proceed.<ref>{{Cite news |url=http://news.bbc.co.uk/2/hi/world/us_and_canada/10454982.stm |title=Pfizer-Nigeria appeal dismissed |work=[[BBC News]] |date=June 29, 2010}}</ref> 

In December 2010, the [[United States diplomatic cables leak]] indicated that Pfizer hired investigators to find evidence of corruption against Nigerian attorney general [[Michael Aondoakaa]] to persuade him to drop legal action.<ref>{{Cite news |last=Boseley |first=Sarah |date=December 9, 2010 |title=WikiLeaks cables: Pfizer 'used dirty tricks to avoid clinical trial payout' |work=The Guardian |location=London |url=https://www.theguardian.com/business/2010/dec/09/wikileaks-cables-pfizer-nigeria}}</ref> ''[[The Washington Post]]'' reporter Joe Stephens, who helped break the story in 2000, called these actions "dangerously close to blackmail".<ref name=DN/> In response, the company released a press statement describing the allegations as "preposterous" and saying that it acted in good faith.<ref>{{Cite press release |url=https://cdn.pfizer.com/pfizercom/news/the_guardian_nigeria_120910.pdf |title=Pfizer Statement Regarding Article In The Guardian |publisher=Pfizer |date=December 9, 2010}}</ref> Aondoakka, who had allegedly demanded bribes from Pfizer in return for a settlement of the case,<ref>{{Cite news |url=https://www.cbsnews.com/news/in-defense-of-blackmail-why-shouldnt-pfizer-dig-dirt-on-crooked-pols/ |title=In Defense of Blackmail: Why Shouldn't Pfizer Dig Dirt on Crooked Pols? |first=Jim |last=Edwards |work=[[CBS News]] |date=January 4, 2011}}</ref> was declared unfit for office and had his U.S. visa revoked in association with corruption charges in 2010.<ref>{{Cite web |title=Michael Aondoakaa "Unfit" To Remain SAN, Says CDHR In High-Powered Petition |url=http://saharareporters.com/2010/07/19/michael-aondoakaa-%E2%80%9Cunfit%E2%80%9D-remain-san-says-cdhr-high-powered-petition |website=Sahara Reporters}}</ref><ref>{{Cite web |title=Wikileaks on Nigeria's Corrupt Oil Sales at NNPC, Shell, US Ambassador |date=December 12, 2010 |url=http://usafricaonline.com/2010/12/12/wikileaks-on-nigerias-oil-corruption-nnpc-shell-us-ambassador-attorney-general-aondoakaa/}}</ref>

The lawsuits were eventually settled out of court. Pfizer committed to paying {{US$|35 million}} "to compensate the families of children in the study", another $30 million to "support healthcare initiatives in Kano", and $10 million to cover legal costs. Payouts began in 2011.<ref>{{cite journal |last1=Lenzer |first1=J. |title=Pfizer settles with victims of Nigerian drug trial |journal=BMJ |date=16 August 2011 |volume=343 |issue=aug16 3 |article-number=d5268 |doi=10.1136/bmj.d5268 |pmid=21846712 |s2cid=8758603}}</ref>

===Inflating prices fine (2022)===
In July 2022, UK antitrust authorities fined Pfizer £63 million for unfairly high priced drug that aids in controlling epileptic seizures. The Competition and Markets Authority stated that the company took advantage of loopholes by de-branding epilepsy drug Epanutin, by doing so the price of Epanutin's price was not regulated to the same standards the company are used to and therefore the price of the drug was raised. It was stated that over a four-year period, Pfizer had billed Epanutin for around 780% and 1,600% higher than its standard price.<ref>{{cite web |url=https://www.bloomberg.com/news/articles/2022-07-21/pfizer-flynn-fined-70-million-for-unfair-epilepsy-drug-prices |title=Pfizer, Flynn Fined £70 Million for Epilepsy Drug Prices |last=Browning |first=Jonny | work=[[Bloomberg News]] |date=July 21, 2022 | url-access=subscription}}</ref>

===Allegations of patent infringement on mRNA technology (2022)===
In August 2022, [[Moderna]] announced that it will sue Pfizer and its partner [[BioNTech]] for [[Patent infringement|infringing their patent]] on the mRNA technology.<ref>{{cite news |last1=Reed |first1=Jim |title=Moderna suing Pfizer over Covid vaccine technology |url=https://www.bbc.com/news/health-62691102 |access-date=2022-08-27 |work=[[BBC News]] |date=2022-08-26}}</ref> In May 2024, the [[European Patent Office]] upheld the validity of Moderna's EP949 patent, one of the two patents asserted against Pfizer and BioNTech.<ref>{{Cite web |title=Moderna wins Covid jab patent dispute over Pfizer and BioNTech |url=https://www.ft.com/content/50c5078c-c9f0-4b35-b916-3475b641c773 |access-date=2024-05-18 |website=www.ft.com|date=May 17, 2024 |last1=Johnston |first1=Ian |last2=Barnes |first2=Oliver }}</ref>

===COVID-19 vaccine controversy ===
In February 2021, after a year long investigation relying on unnamed officials, Pfizer was accused by [[The Bureau of Investigative Journalism]] (TBIJ) of employing "high-level bullying" against at least two [[Latin America]]n countries during negotiations to acquire COVID-19 vaccines, including requesting that the countries put sovereign assets as [[Collateral (finance)|collateral]] for payments.<ref name="bullied">{{Cite news |title=Investigation: Drugmaker 'bullied' Latin American nations |url=https://www.aljazeera.com/news/2021/3/11/investigation-pfizer-bullied-latin-american-nations |website=[[Al Jazeera English]] |date=March 11, 2021}}</ref> According to TBIJ, these negotiation tactics resulted in a months long delay in Pfizer reaching a vaccine agreement with one country and a complete failure to reach agreements with two other countries, including [[Argentina]] and Brazil.<ref name="bullied"/>

In November 2021, TBMJ published an article after obtaining information from a [[whistleblower]] from the Ventavia Research Group. Ventavia was hired by Pfizer as a research subcontractor. A regional director (whistleblower) who was employed at Ventavia Research Group has told ''The BMJ'' that the company falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in [[Pfizer–BioNTech COVID-19 vaccine#Clinical trials|Pfizer's pivotal phase III trial]]. The regional director, Brook Jackson, emailed a complaint to the US [[Food and Drug Administration]] (FDA). Ventavia fired her later the same day.<ref>{{cite news |last1=Thacker |first1=Paul |title=Covid-19: Researcher blows the whistle on data integrity issues in Pfizer's vaccine trial |url=https://www.bmj.com/content/375/bmj.n2635 |access-date=2 November 2021 |publisher=thebmj}}</ref> The [[European Medicines Agency]] (EMA) stated in a response to the [[European Parliament]], that "the deficiencies identified do not jeopardize the quality and integrity of the data from the main Comirnaty trial and have no impact on the benefit-risk assessment or on the conclusions on the safety, effectiveness and quality of the vaccine".<ref>{{Cite web |url=https://www.ema.europa.eu/en/documents/other/ema-reply-letter-members-european-parliament-ms-m-rivasi-mr-p-pedicini-ms-t-metz-concerning-covid-19_en.pdf |title=Reply letter on the Integrity of clinical data, additional clinical trials and studies, pharmacovigilance and mRNA COVID-19 vaccine safety |author=[[European Medicines Agency]] |date=3 December 2021 |access-date=2 February 2022}}</ref> ''[[Science-Based Medicine]]'' emphasized that Ventavia oversaw just three of the 153 clinical sites involved with Pfizer's trial and "a small fraction (~1,000 by the time the whistleblower was fired) of the trial's over ~44,000 subjects."<ref>{{Cite news |last=Gorski |first=David |author-link=David Gorski |date=November 8, 2021 |title=What the heck happened to The BMJ? |work=Science-Based Medicine |url=https://sciencebasedmedicine.org/what-the-heck-happened-to-the-bmj/ |access-date=May 16, 2023}}</ref>

On 10 October 2022, during a session of the [[European Parliament]]'s Special Committee on the COVID-19 Pandemic, Pfizer executive Janine Small testified that the company had not evaluated the [[Pfizer–BioNTech COVID-19 vaccine]] for its ability to reduce transmission of the [[SARS-CoV-2]] virus prior to its release to the general public.<ref>{{Cite web |date=2022-10-10 |title=Special Committee on COVID-19 pandemic |url=https://multimedia.europarl.europa.eu/en/webstreaming/special-committee-on-covid-19-pandemic_20221010-1430-COMMITTEE-COVI |url-status=live |archive-url=https://web.archive.org/web/20221014010053/https://multimedia.europarl.europa.eu/en/webstreaming/special-committee-on-covid-19-pandemic_20221010-1430-COMMITTEE-COVI |archive-date=2022-10-14 |access-date=2022-10-14 |website=[[European Parliament]] Multimedia Centre }}</ref><ref>{{Cite web |last=TN World Desk |date=2022-10-13 |title=Pfizer admits it did not know whether its Covid vaccine prevented transmission of virus when rollout began |url=https://www.timesnownews.com/world/pfizer-admits-it-did-not-know-its-covid-vaccine-prevented-transmission-of-virus-when-rollout-began-article-94836651 |url-status=live |archive-url=https://archive.today/20221013205522/https://www.timesnownews.com/world/pfizer-admits-it-did-not-know-its-covid-vaccine-prevented-transmission-of-virus-when-rollout-began-article-94836651 |archive-date=2022-10-13 |access-date=2022-10-14 |website=[[TimesNow]] }}</ref> Dutch MEP [[Rob Roos]] described the admission as "scandalous".<ref>{{Cite web |last=Chung |first=Frank |date=2022-10-13 |title=Pfizer did not know whether Covid vaccine stopped transmission before rollout, executive admits |url=https://www.news.com.au/technology/science/human-body/pfizer-did-not-know-whether-covid-vaccine-stopped-transmission-before-rollout-executive-admits/news-story/f307f28f794e173ac017a62784fec414 |url-status=live |archive-url=https://web.archive.org/web/20221014110736/https://www.news.com.au/technology/science/human-body/pfizer-did-not-know-whether-covid-vaccine-stopped-transmission-before-rollout-executive-admits/news-story/f307f28f794e173ac017a62784fec414 |archive-date=2022-10-14 |access-date=2022-10-14 |website=[[News.com.au]]}}</ref> CEO [[Albert Bourla]] was slated to attend, but withdrew.<ref>{{Cite web |last=Bauer-Babef |first=Clara |date=2022-10-12 |title=Pfizer remains discreet about COVID vaccine purchase contracts |url=https://www.euractiv.com/section/coronavirus/news/pfizer-remains-discreet-about-covid-vaccine-purchase-contracts/ |url-status=live |archive-url=https://web.archive.org/web/20221013183554/https://www.euractiv.com/section/coronavirus/news/pfizer-remains-discreet-about-covid-vaccine-purchase-contracts/ |archive-date=2022-10-13 |access-date=2022-10-14 |website=[[Euractiv]] -GB}}</ref> Roos' statements in turn have been described as "misleading".<ref>{{Cite web |date=October 18, 2022 |first=Flora |last=Teoh |title=Scientific studies show that the Pfizer-BioNTech COVID-19 vaccine reduces transmission; claim by Rob Roos is misleading |url=https://science.feedback.org/review/scientific-studies-show-pfizer-biontech-covid-19-vaccine-reduces-transmission-claim-rob-roos-misleading/ |url-status=live |archive-url=https://web.archive.org/web/20240916075734/https://science.feedback.org/review/scientific-studies-show-pfizer-biontech-covid-19-vaccine-reduces-transmission-claim-rob-roos-misleading/ |archive-date=September 16, 2024 |access-date=September 16, 2024 |website=Science Feedback |publisher=Health Feedback -GB}}</ref>

==Environmental record==
Since 2000, the company has implemented more than 4,000 [[greenhouse gas]] reduction projects.<ref>{{Cite news |url=https://www.uschamber.com/article/pfizer-implemented-more-4000-greenhouse-gas-reduction-projects-2000 |title=Pfizer Implemented More than 4,000 Greenhouse Gas Reduction Projects Since 2000 |work=[[United States Chamber of Commerce]] |date=November 15, 2019}}</ref>

Pfizer has inherited Wyeth's liabilities in the [[American Cyanamid]] site in [[Bridgewater Township, New Jersey]], a highly toxic EPA [[Superfund]] site. Pfizer has since attempted to remediate this land in order to clean and develop it for future profits and potential public uses.<ref>{{Cite web |title=American Cyanamid Superfund Site Fact Sheet |url=https://www.nj.gov/dep/srp/community/sites/pi/american_cyanamid_fs.pdf |website=[[New Jersey]] |date=December 2011}}</ref> The [[Sierra Club]] and the [[Edison Wetlands Association]] have opposed the cleanup plan, arguing that the area is subject to flooding, which could cause pollutants to leach. The EPA considers the plan the most reasonable from considerations of safety and cost-effectiveness, arguing that an alternative plan involving trucking [[contaminated soil]] off site could expose cleanup workers. The EPA's position is backed by the environmental watchdog group CRISIS.<ref>{{Cite news |title=Activists say EPA $204M fix for polluted American Cyanamid property will not permanently resolve problem |url=https://www.nj.com/news/2012/03/activisits_say_epa_fix_for_pol.html |first=Eugene |last=Paik |work=[[NJ.com]] |date=March 9, 2012}}</ref>

In June 2002, a chemical explosion at the Groton plant injured 7 people and caused the evacuation of more than 100 homes in the surrounding area.<ref>{{cite news |url=https://www.washingtonpost.com/wp-dyn/content/article/2006/05/23/AR2006052301305_pf.html |title=The tempest |newspaper=[[The Washington Post]] |date=May 28, 2006}}</ref>

==Contributions==
Notable organizations to which Pfizer has provided funding include the [[Institute for Advanced Study]],<ref>{{Cite web |last1=Simonyi |first1=Charles |last2=Dijkgraaf |first2=Robbert |date=2018 |title=Report for the Academic Year 2017–2018 |url=https://www.ias.edu/sites/default/files/documents/publications/Annual%20Report%2017%E2%80%9318%20web.pdf |url-status=live |archive-url=https://web.archive.org/web/20220531231144/https://www.ias.edu/sites/default/files/documents/publications/Annual%20Report%2017%E2%80%9318%20web.pdf |archive-date=2022-05-31 |access-date=2022-08-02 |website=[[Institute for Advanced Study]]}}</ref><ref>{{Cite web |last1=Simonyi |first1=Charles |last2=Dijkgraaf |first2=Robbert |date=2014 |title=Report for the Academic Year 2013–2014 |url=https://www.ias.edu/sites/default/files/documents/publications/annualreport1314_0.pdf |url-status=live |archive-url=https://web.archive.org/web/20220802190342/https://www.ias.edu/sites/default/files/documents/publications/annualreport1314_0.pdf |archive-date=2022-08-02 |access-date=2022-08-02 |website=[[Institute for Advanced Study]]}}</ref> [[University of Toronto]],<ref>{{Cite web |title=Donor Listing |url=https://boundless.utoronto.ca/our-supporters/donor-listing/ |url-status=live |archive-url=https://web.archive.org/web/20220530223142/https://boundless.utoronto.ca/our-supporters/donor-listing/ |archive-date=2022-05-30 |access-date=2022-07-01 |website=[[University of Toronto]] }}</ref> and member of the President's Circle.<ref>{{Cite web |date=2022-05-01 |title=Presidents' Circle Member Listing {{!}} Ways to Give |url=https://engage.utoronto.ca/site/SPageServer?pagename=presidents_circle_member_listing |url-status=live |archive-url=https://web.archive.org/web/20220516225544/https://engage.utoronto.ca/site/SPageServer?pagename=presidents_circle_member_listing |archive-date=2022-05-16 |access-date=2022-07-01 |website=[[University of Toronto]]}}</ref> [[University of Washington]],<ref>{{Cite web |date=October 2020 |title=Honor Roll of Donors |url=https://uw-s3-cdn.s3.us-west-2.amazonaws.com/wp-content/uploads/sites/83/2020/10/29094302/RTC_HonorRoll_2020.pdf |url-status=live |archive-url=https://web.archive.org/web/20220610164520/https://uw-s3-cdn.s3.us-west-2.amazonaws.com/wp-content/uploads/sites/83/2020/10/29094302/RTC_HonorRoll_2020.pdf |archive-date=2022-06-10 |access-date=2022-06-10 |website=[[University of Washington]]; [[Amazon Web Services]]}}</ref> [[Habitat for Humanity]],<ref>{{Cite web |last1=Hewitt |first1=Bradford L. |last2=Reckford |first2=Jonathan T.M. |date=2021-11-15 |title=Annual Report FY2021 |url=https://www.habitat.org/media/7101/download |url-status=live |archive-url=https://web.archive.org/web/20220721071822/https://www.habitat.org/media/7101/download |archive-date=2022-07-21 |access-date=2022-07-21 |website=[[Habitat for Humanity]]}}</ref> [[Human Rights Campaign]],<ref>{{Cite web |title=Corporate Partners |url=https://www.hrc.org/about/corporate-partners |url-status=live |archive-url=https://web.archive.org/web/20220714072833/https://www.hrc.org/about/corporate-partners |archive-date=2022-07-14 |access-date=2022-07-14 |website=[[Human Rights Campaign]]}}</ref> [[National Women's Law Center]],<ref>{{Cite web |date=2016 |title=Annual Report FY 2015–2016 |url=https://nwlc.org/wp-content/uploads/2021/11/final_FY2015-2016_NWLC_AnnualReport.pdf |url-status=live |archive-url=https://web.archive.org/web/20220420023726/https://nwlc.org/wp-content/uploads/2021/11/final_FY2015-2016_NWLC_AnnualReport.pdf |archive-date=2022-04-20 |access-date=2022-07-04 |website=[[National Women's Law Center]]}}</ref> [[Share Our Strength]],<ref>{{Cite web |last1=Shore |first1=Billy |last2=Nelson |first2=Tom |date=2017 |title=No Kid Hungry 2017 |url=https://www.shareourstrength.org/wp-content/uploads/2018/05/AnnualReport_2017_mid.pdf |access-date=2022-07-03 |website=Share Our Strength}}</ref> [[WaterAid]],<ref>{{Cite web |date=2011 |title=Investments in Health – Pfizer 2010 Annual Review |url=https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2010/access-investments.html |url-status=live |archive-url=https://web.archive.org/web/20220812064428/https://www.pfizer.com/sites/default/files/investors/financial_reports/annual_reports/2010/access-investments.html |archive-date=2022-08-12 |access-date=2022-08-12 }}</ref> [[National Geographic]],<ref>{{Cite magazine |last=Snyder Bulik |first=Beth |date=2021-02-24 |title='Mission Possible': Pfizer and BioNTech star in their own vaccine discovery movie |url=https://www.fiercepharma.com/marketing/mission-possible-pfizer-and-biontech-star-vaccine-discovery-movie |url-status=live |archive-url=https://archive.today/20220408053736/https://www.fiercepharma.com/marketing/mission-possible-pfizer-and-biontech-star-vaccine-discovery-movie |archive-date=April 8, 2022 |access-date=2022-04-08 |website=Fierce Pharma  | publisher=[[Questex]]}}</ref> [[National Geographic Society]],<ref>{{Cite web |date=2016 |title=The Power of Philanthropy |url=https://media.nationalgeographic.org/assets/file/2016_Annual_Report_DONOR_LIST_FINAL.pdf |url-status=live |archive-url=https://web.archive.org/web/20220510054615/https://media.nationalgeographic.org/assets/file/2016_Annual_Report_DONOR_LIST_FINAL.pdf |archive-date=2022-05-10 |access-date=2022-05-10 |website=National Geographic}}</ref> [[94th Academy Awards]],<ref>{{Cite magazine |last=Adams |first=Ben |date=2022-03-28 |title=Pfizer and BioNTech go to Hollywood with splashy Oscars sponsorship |url=https://www.fiercepharma.com/marketing/pfizer-and-biontech-take-hollywood-they-sponsor-oscars |url-status=live |archive-url=https://archive.today/20220330175317/https://www.fiercepharma.com/pharma/lipocine-antares-score-fda-nod-trt-tlando-oral-treatment-hypogonadism |archive-date=March 30, 2022 |access-date=2022-05-23 |magazine=Fierce Pharma | publisher=[[Questex]]}}</ref> [[National Press Foundation]],<ref>{{Cite web |date=2013 |title=National Press Foundation |url=http://nationalpress.org/about/our-funders/ |archive-url=https://web.archive.org/web/20130128213106/http://nationalpress.org/about/our-funders/ |archive-date=2013-01-28 |access-date=2022-05-24 |website=[[National Press Foundation]]}}</ref><ref>{{Cite web |date=2010 |title=Our Funders |url=http://nationalpress.org/about/our-funders/ |archive-url=https://web.archive.org/web/20100926162431/http://nationalpress.org/about/our-funders/ |archive-date=2010-09-26 |access-date=2022-05-24 |website=[[National Press Foundation]]}}</ref><ref>{{Cite web |date=2010 |title=Cancer Issues 2010 |url=http://nationalpress.org/programs-and-resources/program/cancer-issues-2010/ |archive-url=https://web.archive.org/web/20100830005040/http://nationalpress.org/programs-and-resources/program/cancer-issues-2010/ |archive-date=2010-08-30 |access-date=2022-05-24 |website=National Press Foundation}}</ref><ref>{{Cite web |last=Raeburn |first=Paul |date=2010-10-13 |title=Cover this great cancer conference! (Yes, there's a catch...) |url=https://ksj.mit.edu/tracker-archive/cover-great-cancer-conference-yes-theres/ |url-status=live |archive-url=https://web.archive.org/web/20220524144432/http://ksj.mit.edu/tracker-archive/cover-great-cancer-conference-yes-theres/ |archive-date=2022-05-24 |access-date=2022-05-24 |website=[[Knight Science Journalism]] @MIT }}</ref> [[19 to Zero]],<ref>{{Cite web |date=2021-06-03 |title=Who We Are |url=https://www.19tozero.ca/who-we-are |archive-url=https://web.archive.org/web/20220719223946/https://www.19tozero.ca/who-we-are |archive-date=July 19, 2022 |access-date=2022-06-19 |website=19 to Zero}}</ref> [[American Society of Hematology]],<ref>{{Cite web |title=Corporate Support |url=https://www.hematology.org/about/corporate-support |url-status=live |archive-url=https://archive.today/20220610180740/https://www.hematology.org/about/corporate-support |archive-date=June 10, 2022 |access-date=2022-06-10 |website=[[American Society of Hematology]] }}</ref> [[Canadian Cancer Society]],<ref>{{Cite web |title=Our Corporate Partners |url=https://cancer.ca/en/get-involved/partnerships/our-corporate-partners |url-status=live |archive-url=https://archive.today/20220502135839/https://cancer.ca/en/get-involved/partnerships/our-corporate-partners |archive-date=May 2, 2022 |access-date=2022-05-15 |website=[[Canadian Cancer Society]] }}</ref> [[Canadian Paediatric Society]],<ref>{{Cite web |last=Public Health Agency of Canada |date=2022-02-25 |title=National Advisory Committee on Immunization (NACI): Membership and representation |url=https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html |url-status=live |archive-url=https://web.archive.org/web/20220323061520/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html#fn1-rf |archive-date=2022-03-23 |access-date=2022-03-29 |website=[[Government of Canada]]}}</ref> [[Endocrine Society]],<ref>{{Cite web |title=Corporate Liaison Board |url=https://www.endocrine.org/membership/corporate-liaison-board |url-status=live |archive-url=https://archive.today/20220610234024/https://www.endocrine.org/membership/corporate-liaison-board |archive-date=June 10, 2022 |access-date=2022-06-10 |website=[[Endocrine Society]] }}</ref> and [[European Society of Cardiology]].<ref>{{Cite web |title=Why sponsor the EURObservational Registry Programme |url=https://www.escardio.org/Research/Registries-%26-surveys/Sponsorship%2C%20https%3A//www.escardio.org/Research/Registries-%26-surveys/Sponsorship |url-status=live |archive-url=https://archive.today/20220615200912/https://www.escardio.org/Research/Registries-&-surveys/Sponsorship |archive-date=June 15, 2022 |access-date=2022-06-15 |website=[[European Society of Cardiology]] }}</ref>

The company spends $10-15 million per year on lobbying in the United States.<ref>{{Cite web | url=https://www.opensecrets.org/federal-lobbying/clients/summary?cycle=2025&id=D000000138&name=Pfizer+Inc | title=Client Profile: Pfizer Inc | work=[[OpenSecrets]]}}</ref> It also lobbies the [[Government of Ontario]] and [[House of Commons of Canada]] through Rubicon Strategy, a firm owned by [[Progressive Conservative Party of Ontario]] campaign manager [[Kory Teneycke]].<ref>{{Cite web |date=2021-09-22 |title=Consultant Lobbyist Registration No. CL4899-20200917025456 |url=https://lobbyist.oico.on.ca/Pages/Public/PublicSearch/ | work=Office of the Integrity Commissioner of Ontario |archive-url=https://web.archive.org/web/20220308181206/https://lobbyist.oico.on.ca/Pages/Public/PublicSearch/ |archive-date=March 8, 2022 |url-status=live }}</ref><ref>{{Cite web |last=Maher |first=Stephen |date=2019-01-29 |title=For access to the Ford government, two names matter most |url=https://www.macleans.ca/politics/for-access-to-the-ford-government-two-names-matter-most/ | work=[[MacLean's]] |archive-url=https://archive.today/20210322062629/https://www.macleans.ca/politics/for-access-to-the-ford-government-two-names-matter-most/ |archive-date=March 22, 2021 |url-status=live}}</ref><ref>{{Cite web | work=Registry of Lobbyists |date=2022-03-28 |title=Innovative Medicines Canada/Médicaments Novateurs Canada / Andrew Balfour, Consultant | url=https://lobbycanada.gc.ca/app/secure/ocl/lrs/do/clntSmmry?clientOrgCorpNumber=367878&sMdKy=1621857998861 |archive-url=https://archive.today/20220408060852/https://lobbycanada.gc.ca/app/secure/ocl/lrs/do/clntSmmry?clientOrgCorpNumber=367878&sMdKy=1621857998861 |archive-date=April 8, 2022|url-status=live }}</ref> Pfizer lobbied various officials in the [[Government of British Columbia]] between April and November 2012, including then-premier [[Christy Clark]], future premier [[John Horgan]], future health minister [[Adrian Dix]], and future deputy premier, minister of public safety and solicitor general [[Mike Farnworth]].<ref>{{Cite web |date=2012-04-10 |title=Registration ID: 200777 |url=https://www.lobbyistsregistrar.bc.ca/app/secure/orl/lrs/do/vwRg?cno=2406&regId=200777 | work=BC Office of the Registrar of Lobbyists |archive-url=https://archive.today/20220426232441/https://www.lobbyistsregistrar.bc.ca/app/secure/orl/lrs/do/vwRg?cno=2406&regId=200777 |archive-date=April 26, 2022 |url-status=live }}</ref>

Notable professional associations to which Pfizer has contributed include [[American Statistical Association]],<ref>{{Cite web |title=ASA Organizational Members |url=https://ww2.amstat.org/membership/corporatesupporters.cfm |url-status=live |archive-url=https://web.archive.org/web/20230529193058/https://ww2.amstat.org/membership/corporatesupporters.cfm |archive-date=2023-05-29 |access-date=2023-05-29 |website=[[American Statistical Association]]}}</ref> [[Canadian Association of Emergency Physicians]],<ref>{{Cite web |date=2019 |title=Annual Report 2018-2019 |url=https://caep.ca/wp-content/uploads/2019/06/Annual-Report2019-V2.pdf |url-status=live |archive-url=https://web.archive.org/web/20220420013556/https://caep.ca/wp-content/uploads/2019/06/Annual-Report2019-V2.pdf |archive-date=2022-04-20 |access-date=2022-06-18 |website=[[Canadian Association of Emergency Physicians]]}}</ref> [[Canadian Medical Association]],<ref>{{Cite news |last=Weeks |first=Carly |date=2009-12-02 |title=Medical association takes heat for Pfizer funding -CA |work=The Globe and Mail |url=https://www.theglobeandmail.com/life/health-and-fitness/medical-association-takes-heat-for-pfizer-funding/article568583/ |access-date=2022-06-09}}</ref> [[Canadian Pharmacists Association]], [[Canadian Pharmacists Journal]],<ref>{{Cite journal |date=May 2014 |title=Meet Our Sponsors |journal=Canadian Pharmacists Journal / Revue des Pharmaciens du Canada |volume=147 |issue=3 |pages=191–192 |doi=10.1177/1715163514530860 |issn=1715-1635 |pmc=4025887 |pmid=24847373 }}</ref> [[Canadian Public Health Association]],<ref>{{Cite web |title=2018 Annual Report |url=https://www.cpha.ca/sites/default/files/uploads/about/reports/2018-annual-report-web-e.pdf |url-status=live |archive-url=https://web.archive.org/web/20210608184141/https://www.cpha.ca/sites/default/files/uploads/about/reports/2018-annual-report-web-e.pdf |archive-date=2021-06-08 |access-date=2022-03-18 |website=Canadian Public Health Association}}</ref> [[Ontario Medical Association]],<ref>{{Cite web |date=2022 |title=Your impact |url=https://www.oma.org/what-we-do/ontario-medical-foundation/your-impact/ |url-status=live |archive-url=https://web.archive.org/web/20220609072754/https://www.oma.org/what-we-do/ontario-medical-foundation/your-impact/ |archive-date=2022-06-09 |access-date=2022-07-01 |website=[[Ontario Medical Association]]}}</ref> [[Centre for Addiction and Mental Health]],<ref>{{Cite web |date=2021 |title=Thank you to our donors |url=https://www.camh.ca/-/media/files/camhf-2020-21-annual-report-donor-listing.pdf |url-status=live |archive-url=https://web.archive.org/web/20220619084300/https://www.camh.ca/-/media/files/camhf-2020-21-annual-report-donor-listing.pdf |archive-date=2022-06-19 |access-date=2022-07-01 |website=[[Centre for Addiction and Mental Health]]}}</ref> [[Dana–Farber Cancer Institute]],<ref>{{Cite web |title=2012 Honor Roll of Donors |url=https://www.pageturnpro.com/Dana-Farber-Cancer-Institute-and-The-Jimmy-Fund/49214-2012-Honor-Roll-of-Donors/sdefault.html#page/8 |access-date=2022-08-13 |website=[[Dana–Farber Cancer Institute]]; PageTurnPro}}</ref> [[Hospital for Sick Children (Toronto)|Hospital for Sick Children (SickKids)]],<ref>{{Cite web |date=2021 |title=2020–21 SickKids Annual Report |url=https://web.sickkidsfoundation.com/annual-report-2020/ |url-status=live |archive-url=https://web.archive.org/web/20220620073404/https://web.sickkidsfoundation.com/annual-report-2020/ |archive-date=2022-06-20 |access-date=2022-07-01 |website=[[SickKids|SickKids Foundation]]}}</ref> [[North Bay Regional Health Center]],<ref>{{Cite web |date=2019 |title=Donor List |url=https://nbrhc.on.ca/wp-content/uploads/2019/12/2019-Donor-Wall-List.doc |url-status=live |archive-url=https://web.archive.org/web/20220701202805/https://nbrhc.on.ca/wp-content/uploads/2019/12/2019-Donor-Wall-List.doc |archive-date=2022-07-01 |access-date=2022-07-01 |website=[[North Bay Regional Health Center]]}}</ref> [[Princess Margaret Cancer Centre]],<ref>{{Cite web |title=The 8th Princess Margaret Hospital Conference: Developments in Cancer Management |url=https://fdocuments.in/document/years-of-success-anna-greenberg-richard-hill-michael-jewett-david-mccready-hans.html |url-status=live |archive-url=https://web.archive.org/web/20220620072213/https://fdocuments.in/document/years-of-success-anna-greenberg-richard-hill-michael-jewett-david-mccready-hans.html?page=1 |archive-date=2022-06-20 |access-date=2022-07-01 |website=FDocuments India }}</ref><ref>{{Cite web |date=2021 |title=2021 Annual Report |url=https://thepmcf.ca/getmedia/9b96649e-83ba-490a-bacc-f961904b94c8/Annual-Report-2021_Digital.pdf |url-status=live |archive-url=https://web.archive.org/web/20211120191604/https://thepmcf.ca/getmedia/9b96649e-83ba-490a-bacc-f961904b94c8/Annual-Report-2021_Digital.pdf |archive-date=2021-11-20 |access-date=2022-07-01 |website=Princess Margaret Cancer Foundation}}</ref> [[Scarborough Health Network]],<ref>{{Cite web |date=2021 |title=Our Donors |url=https://www.shnfoundation.ca/our-donors/ |url-status=live |archive-url=https://web.archive.org/web/20220620072949/https://www.shnfoundation.ca/our-donors/ |archive-date=2022-06-20 |access-date=2022-07-01 |website=[[Scarborough Health Network|Scarborough Health Network Foundation]] -CA}}</ref> [[Sinai Health System|Sinai Health Foundation]], including [[Mount Sinai Hospital (Toronto)|Mount Sinai Hospital]], [[Bridgepoint Active Healthcare]], and the [[Lunenfeld-Tanenbaum Research Institute]],<ref>{{Cite web |title=Donor List – 2020–2021 |url=https://www.sinaihealthannualreport.ca/donor-list-2020-2021 |url-status=live |archive-url=https://web.archive.org/web/20220516074559/https://www.sinaihealthannualreport.ca/donor-list-2020-2021 |archive-date=2022-05-16 |access-date=2022-05-16 |website=Sinai Health Annual Report}}</ref> [[Sunnybrook Health Sciences Centre]] – Donor.<ref>{{Cite web |date=2022 |title=Our donors – Your Impact |url=https://sunnybrook.ca/foundation/your-impact/our-donors-2021.html |url-status=live |archive-url=https://web.archive.org/web/20220620153915/https://sunnybrook.ca/foundation/your-impact/our-donors-2021.html |archive-date=2022-06-20 |access-date=2022-07-01 |website=[[Sunnybrook Health Sciences Centre|Sunnybrook Foundation]] }}</ref> [[William Osler Health System]],<ref>{{Cite web |title=Holi Gala Festival of Colours 2022 |url=https://support.oslerfoundation.org/site/SPageServer?pagename=holigala22_our_sponsors |url-status=live |archive-url=https://archive.today/20220617074329/https://support.oslerfoundation.org/site/SPageServer?pagename=holigala22_our_sponsors |archive-date=June 17, 2022 |access-date=2022-06-17 |website=[[William Osler Health System]] }}</ref> [[Ronald McDonald House Charities]],<ref>{{Cite web |title=Corporate Sponsors of RMHC |url=https://rmhc.org/about-us/our-partners |url-status=live |archive-url=https://web.archive.org/web/20220512061331/https://rmhc.org/about-us/our-partners |archive-date=2022-05-12 |access-date=2022-06-08 |website=[[Ronald McDonald House Charities]] }}</ref> [[AdvaMed]],<ref>{{Cite web |date=2014-07-13 |title=Members |url=http://advamed.org/page/33/members |url-status=usurped |archive-url=https://web.archive.org/web/20140713182356/http://advamed.org/page/33/members |archive-date=2014-07-13 |access-date=2022-06-13 |website=[[AdvaMed]]}}</ref> [[Arthritis Australia]],<ref>{{Cite web |title=Our Supporters |url=https://arthritisaustralia.com.au/about-us/our-supporters/ |access-date=2022-06-13 |website=Arthritis Australia -AU}}</ref> [[Drugs for Neglected Diseases Initiative]],<ref>{{Cite web |date=2020-04-24 |title=Our partners |url=https://dndi.org/partnerships/industry-partners/ |url-status=live |archive-url=https://archive.today/20220603181048/https://dndi.org/partnerships/industry-partners/ |archive-date=June 3, 2022 |access-date=2022-06-06 |website=[[Drugs for Neglected Diseases Initiative]] -GB }}</ref> [[GISAID]],<ref>{{Cite web |date=2022 |title=Grants and Donations |url=https://www.gisaid.org/about-us/grants-and-donations/ |url-status=live |archive-url=https://web.archive.org/web/20220620035459/https://www.gisaid.org/about-us/grants-and-donations/ |archive-date=2022-06-20 |access-date=2022-07-01 |website=[[GISAID]]}}</ref> [[Heart and Stroke Foundation of Canada]],<ref>{{Cite web |title=Our partners |url=https://www.heartandstroke.ca/en/what-we-do/partners/ |url-status=live |archive-url=https://archive.today/20220509221919/https://www.heartandstroke.ca/what-we-do/partners |archive-date=May 9, 2022 |access-date=2022-05-16 |website=Heart and Stroke Foundation of Canada }}</ref><ref>{{Cite web |date=2018-04-27 |title=Pfizer Canada announces support to Heart & Stroke's #TimeToSeeRed campaign |url=https://www.pfizer.ca/pfizer-canada-announces-support-heart-stroke%E2%80%99s-timetoseered-campaign |url-status=live |archive-url=https://web.archive.org/web/20220516183729/https://www.pfizer.ca/pfizer-canada-announces-support-heart-stroke%E2%80%99s-timetoseered-campaign |archive-date=2022-05-16 |access-date=2022-05-16 |website=Pfizer Canada }}</ref> [[Mount Sinai Hospital (Toronto)]],<ref>{{Cite web |title=COVID-19 Cohort Study (CCS): Study of the epidemiology of COVID-19 in healthcare workers and their households |url=https://www.tibdn.ca/covid-19/sinai |url-status=live |archive-url=https://web.archive.org/web/20220516190343/https://www.tibdn.ca/covid-19/sinai |archive-date=2022-05-16 |access-date=2022-05-16 |website=TIBDN: Toronto Invasive Bacterial Diseases Network }}</ref> and [[Truth Initiative]].<ref>{{Cite web |date=2022 |title=Featured partnerships |url=https://truthinitiative.org/what-we-do/partnerships/featured-partnerships |url-status=live |archive-url=https://web.archive.org/web/20220721005439/https://truthinitiative.org/what-we-do/partnerships/featured-partnerships |archive-date=2022-07-21 |access-date=2022-07-21 |website=[[Truth Initiative]] }}</ref>

Notable lobbying organizations to which the company has contributed include [[BIOTECanada]],<ref>{{Cite web |date=2021-12-23 |title=Member Listings |url=https://www.biotech.ca/about/member-listings/ | work=[[BIOTECanada]] |archive-url=https://web.archive.org/web/20220502074149/https://www.biotech.ca/about/member-listings/ |archive-date=2022-05-02 |url-status=live }}</ref><ref>{{Cite news |last=Wilson |first=Barry |date=2000-10-05 |title=Biotech lobby group at heart of ethics complaint |url=https://www.producer.com/news/biotech-lobby-group-at-heart-of-ethics-complaint/ | work=[[The Western Producer]] |archive-url=https://archive.today/20220618172657/https://www.producer.com/news/biotech-lobby-group-at-heart-of-ethics-complaint/ |archive-date=June 18, 2022 |url-status=live}}</ref> [[Bipartisan Policy Center]],<ref>{{Cite web |date=2021 |title=2020–2021 Annual Report | url=https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2021/06/BPC-Annual-Report_6.8.pdf |  work=[[Bipartisan Policy Center]]|archive-url=https://web.archive.org/web/20220514184516/https://bipartisanpolicy.org/download/?file=/wp-content/uploads/2021/06/BPC-Annual-Report_6.8.pdf |archive-date=2022-05-14 |url-status=live}}</ref> [[The Business Council]],<ref>{{Cite web |date=2022 |title=Active Members |url=https://businesscouncil.com/active-members/ | work=[[The Business Council]] |archive-url=https://web.archive.org/web/20220713065022/https://businesscouncil.com/active-members/ |archive-date=2022-07-13 |url-status=live}}</ref> [[United Nations Foundation|Business Council for the United Nations]],<ref>{{Cite web |title=Members |url=https://www.businesscouncilfortheun.org/bcun-members | work=Business Council for the United Nations |archive-url=https://archive.today/20220517151340/https://www.businesscouncilfortheun.org/bcun-members |archive-date=2022-05-17 |url-status=live }}</ref> [[Center on Budget and Policy Priorities]],<ref>{{Cite web |date=2013 |title=2013 Foundation and Institutional Support | url=https://www.cbpp.org/sites/default/files/atoms/files/foundationlist2013final.pdf | work=[[Center on Budget and Policy Priorities]] | archive-url=https://web.archive.org/web/20220617124921/https://www.cbpp.org/sites/default/files/atoms/files/foundationlist2013final.pdf |archive-date=2022-06-17 |url-status=live }}</ref> [[European Federation of Pharmaceutical Industries and Associations]],<ref>{{Cite web |date=2022 |title=Membership |url=https://www.efpia.eu/about-us/membership/ | work=EFPIA |archive-url=https://web.archive.org/web/20220701031757/https://www.efpia.eu/about-us/membership/ |archive-date=2022-07-01 |url-status=live}}</ref> [[Foundation for the National Institutes of Health]],<ref>{{Cite web |title=2020 Donors |url=https://2020-annual-report.fnih.org/donors/ | work=FNIH 2020 Annual Report |archive-url=https://web.archive.org/web/20220402180716/https://2020-annual-report.fnih.org/donors/ |archive-date=2022-04-02 |url-status=live}}</ref> [[Global Health Council]],<ref>{{Cite web |title=Members |url=https://globalhealth.org/about-us/members/ | work=[[Global Health Council]] |archive-url=https://web.archive.org/web/20220726224915/https://globalhealth.org/about-us/members/ |archive-date=2022-07-26 |url-status=live }}</ref> [[Innovative Medicines Canada]],<ref>{{Cite web |title=Member Companies |url=http://innovativemedicines.ca/about/member-companies/ | work=Innovative Medicines Canada |archive-url=https://archive.today/20211103040804/http://innovativemedicines.ca/about/member-companies/ |archive-date=November 3, 2021 |url-status=live }}</ref><ref>{{Cite news |url=https://www.theglobeandmail.com/canada/article-innovative-medicines-canada-bans-members-from-paying-doctors-fees-for/ |last=Grant |first=Kelly |title=Innovative Medicines Canada bans members from paying doctors fees for IV infusions -CA |work=[[The Globe and Mail]] |date=2019-12-11 }}</ref> [[International Federation of Pharmaceutical Manufacturers & Associations]],<ref>{{Cite web |title=Companies |url=https://www.ifpma.org/who-we-are/our-membership/full-members/companies/ | work=[[International Federation of Pharmaceutical Manufacturers and Associations]] |archive-url=https://web.archive.org/web/20220701150736/https://www.ifpma.org/who-we-are/our-membership/full-members/companies/#!/ |archive-date=2022-07-01 |url-status=live}}</ref> [[National Health Council]],<ref>{{Cite web |title=Our Members |url=https://nationalhealthcouncil.org/members/ | work=National Health Council|archive-url=https://web.archive.org/web/20220406081753/https://nationalhealthcouncil.org/members/?m_cat=74&m_key= |archive-date=2022-04-06 |url-status=live}}</ref> [[Pharmaceutical Advertising Advisory Board]],<ref>{{Cite web |title=Our Organization |url=https://www.paab.ca/about.htm | work=[[Pharmaceutical Advertising Advisory Board]] |archive-url=https://web.archive.org/web/20220425051012/https://www.paab.ca/about.htm |archive-date=2022-04-25 |url-status=live}}</ref> [[Pharmaceutical Research and Manufacturers of America]],<ref>{{Cite web |title=About |url=https://www.phrma.org/about | work=PhRMA |archive-url=https://archive.today/20220406052447/https://www.phrma.org/about |archive-date=April 6, 2022 |url-status=live }}</ref><ref>{{Cite web |last=Schwartz |first=Brian |date=2021-06-01 |title=Big Pharma lobbyists launch campaign against Biden over Covid vaccine patent waiver |url=https://www.cnbc.com/2021/06/01/big-pharma-launches-campaign-against-biden-over-covid-vaccine-patent-waiver.html |work=[[CNBC]] |archive-url=https://archive.today/20210602022055/https://www.cnbc.com/2021/06/01/big-pharma-launches-campaign-against-biden-over-covid-vaccine-patent-waiver.html |archive-date=June 2, 2021 |url-status=live }}</ref> [[Reagan-Udall Foundation]],<ref>{{Cite web |date=2021 |title=2021 Annual Report |url=https://reaganudall.org/about-us/annual-reports/2021-annual-report | work=[[Reagan-Udall Foundation]] |archive-url=https://web.archive.org/web/20220712045554/https://reaganudall.org/about-us/annual-reports/2021-annual-report |archive-date=2022-07-12 |url-status=live}}</ref> [[U.S. Global Leadership Coalition]],<ref>{{Cite web |url=https://www.usglc.org/about-us/coalition-members/ |title=U.S. Global Leadership Coalition, Global Trust members |publisher=[[U.S. Global Leadership Coalition]]}}</ref> and [[World Economic Forum]].<ref>{{Cite web |last=Ivan |first=Wecke |date=2021-08-16 |title=Conspiracy theories aside, there is something fishy about the Great Reset |url=https://www.opendemocracy.net/en/oureconomy/conspiracy-theories-aside-there-something-fishy-about-great-reset/ | work=openDemocracy |archive-url=https://archive.today/20220404023305/https://www.opendemocracy.net/en/oureconomy/conspiracy-theories-aside-there-something-fishy-about-great-reset/ |archive-date=April 4, 2022 |url-status=live}}</ref><ref>{{Cite web |title=Pfizer | work=[[World Economic Forum]] |url=https://www.weforum.org/organizations/pfizer/ |archive-url=https://archive.today/20220314092916/https://www.weforum.org/organizations/pfizer |archive-date=March 14, 2022 |url-status=live }}</ref>

[[Scott Gottlieb]], who resigned as [[FDA commissioner]] in April 2019, joined the Pfizer [[board of directors]] in July 2019.<ref>{{Cite news |last=Mishra |first=Manas |date=July 2, 2019 |title=Senator Warren asks former FDA chief Gottlieb to resign from Pfizer board |work=[[Reuters]] |editor-last=Kuber |editor-first=Shailesh |url=https://www.reuters.com/article/us-pfizer-board-scott-gottlieb/senator-warren-asks-former-fda-chief-gottlieb-to-resign-from-pfizer-board-idUSKCN1TX2IX}}</ref>

=== Philanthropy ===
=== The Pfizer Award === 
The Pfizer Award, established in 1958 by Pfizer, Inc., recognizes exceptional books on the history of science. The prize includes a medal and $2,500. Eligible books must be published in English within the three years preceding the competition year (e.g., for 2024, books from 2021–2023). Edited volumes and books with more than two authors are excluded, though multi-volume works by one or two authors may qualify once all volumes are published. While books with themes in medicine or technology may be considered, the award prioritizes works focused on the history of science. The prize is not divided between multiple books.<ref name="hssonline.org/page">{{cite web |title=Pfizer Award |url=https://hssonline.org/page/pfizeraward |website=hssonline.org/page |access-date=25 March 2025}}</ref>

=== The Royal Society Pfizer Award/The Royal Society Africa Prize === 
The Royal Society Pfizer Award, established in 2006 with support from Pfizer Inc., recognized African research scientists contributing innovatively to biological and basic medical sciences, with a focus on capacity building in Africa. Recipients received a bronze medal, £1,000, and an £11,000 research grant for a project affiliated with an African scientific institution, such as a university or research center. The award was last presented in 2016 and has since been replaced by the Royal Society Africa Prize.<ref>{{cite web |title=Royal Society Pfizer Award |url=https://royalsociety.org/medals-and-prizes/pfizer-award/ |website=The Royal Society |access-date=7 April 2025}}</ref>

==== The Pfizer Foundation ====
The Pfizer Foundation, established in 1953, is a charitable organization dedicated to building healthier communities worldwide. It operates independently of Pfizer Inc., with its mission centered on addressing global health challenges, supporting urgent health needs, and empowering Pfizer employees to create meaningful impacts in their communities.<ref>{{cite web |title=The Pfizer Foundation |url=https://www.devex.com/organizations/the-pfizer-foundation-108612 |website=[[Devex]] |access-date=1 February 2025}}</ref><ref>{{cite web |title=Pfizer Foundation |url=https://www.insidephilanthropy.com/find-a-grant/grants-p/pfizer-foundation |website=[[Inside Philanthropy]] |date=July 26, 2023 |access-date=21 March 2025}}</ref>

The foundation also supports specific initiatives such as improving breast cancer care in [[Rwanda]], empowering women and driving progress through Integrated Health Services in [[Benin]], addressing vaccine access for zero-dose children in [[Nigeria]], and collaborating with organizations like [[Direct Relief]] to strengthen healthcare providers in the United States.<ref>{{cite web |title=Direct Relief and The Pfizer Foundation Support 19 Programs to Improve Infectious Disease Care in the United States |url=https://www.directrelief.org/2023/08/direct-relief-and-the-pfizer-foundation-support-19-programs-to-improve-infectious-disease-care-in-the-united-states/ |website=[[Direct Relief]] |date=August 29, 2023 |access-date=21 March 2025}}</ref>

==Awards and recognitions==
Pfizer has received numerous accolades and recognitions worldwide for its efforts in fostering an inclusive and equitable work environment beside the pharmaceutical activities. 

In the United States, Pfizer earned a 100% score from the [[Human Rights Campaign]] (2025) on the Corporate Equality Index for [[LGBTQ]] workplace equality <ref>{{cite web |title=Message from HRC's President |url=https://reports.hrc.org/corporate-equality-index-2025 |website=Human Rights Campaign|author= Kelley Robinson |access-date=26 March 2025}}</ref> and ranked highly in the Hispanic Association on Corporate Responsibility (2024) Corporate Inclusion Index. Pfizer was named a "Best Place to Work for Disability Inclusion" in the Disability Equality Index (2024) and received awards such as Top Diverse Employer, Top Hispanic Employer, and Top Disability-Friendly Company by DiversityComm, Inc. (2024). Other recognitions include being named one of "America's Greatest Workplaces" by [[Newsweek]] (2023),<ref>{{cite web |title=America's Greatest Workplaces 2023 |url=https://www.newsweek.com/rankings/americas-greatest-workplaces-2023 |author=Nancy Cooper|website=Newsweek |date=July 5, 2023 |access-date=7 April 2025}}</ref> Clinical Trials Arena Excellence Awards 2023, inclusion in the top 10 of the "World's Most Admired Companies" by Fortune (2023), and being listed as a Top Employer for Diversity and Best Employer for Women by Forbes (2022). Pfizer was also recognized as a "Best Place to Work" by [[Glassdoor]] (2021) and a Top Employer by Science (2021) for its practices during the pandemic.<ref name="pharmavoice.com/news">{{cite web |title=5 of the best places to work in pharma, according to employees |url=https://www.pharmavoice.com/news/5-best-places-to-work-pharma-glassdoor-merck/692053/ |date=29 August 2023|author= Alexandra Pecci|website=PharmaVoice |access-date=1 February 2025}}</ref>

=== Pfizer For All === 
Pfizer introduced PfizerForAll, a digital platform designed to streamline access to healthcare and wellness resources in the United States. The platform supports individuals with common conditions like the flu, COVID-19, and migraines, as well as those seeking adult vaccinations.<ref>{{cite web |title=Pfizer Launches PfizerForAll to Simplify Healthcare Access |url=https://thehealthcaretechnologyreport.com/pfizer-launches-pfizerforall-to-simplify-healthcare-access/ |website=The Healthcare Technology Report|date=2025-01-01 |access-date=2025-04-04}}</ref> It integrates services such as same-day access to healthcare professionals, home delivery of prescriptions and diagnostic tests, appointment scheduling, and financial assistance for Pfizer medications. Partnering with organizations like UpScriptHealth, Alto Pharmacy, and [[Instacart]], PfizerForAll aims to simplify tasks like prescription fulfillment and accessing savings programs. Pfizer plans to expand the platform to address a wider range of healthcare needs and enhance user experience.<ref>{{cite web |title='Pfizer for All' consumer platform aims to provide post-Covid boost |url=https://www.ft.com/content/772794b4-0dd8-4ba1-a356-bc5f33c21589 |website=The Financial Times|date=May 12, 2024 |access-date=4 April 2025 |last1=Barnes |first1=Oliver }}</ref><ref>{{cite web |title=Pfizer Launches Consumer Access Program for Vaccines and Some Medications |url=https://www.managedhealthcareexecutive.com/view/pfizer-launches-consumer-access-program-for-vaccines-and-some-medications |website=Managed Healthcare Executive |author=Denise Myshko|date=27 August 2024|access-date=4 April 2025}}</ref>

== Corporate affairs ==
=== Board of directors ===
{{As of|2024|12}}, the company's [[Board of directors|board]] consisted of the following directors:<ref name=10K/>

* Ronald E. Blaylock, Managing Partner of GenNx360 Capital Partners
* [[Albert Bourla]], CEO of Pfizer
* [[Mortimer J. Buckley]], former CEO of [[The Vanguard Group]]
* [[Sue Desmond-Hellmann]], former CEO of [[The Bill and Melinda Gates Foundation]]
* Joseph J. Echevarria, former CEO of [[Deloitte LLP]]
* [[Scott Gottlieb]], former [[Commissioner of Food and Drugs|Commissioner]] of the [[Food and Drug Administration|FDA]]
* [[Helen Hobbs]], Professor at the [[University of Texas Southwestern Medical Center]]
* [[Susan Hockfield]], [[List of presidents of the Massachusetts Institute of Technology|16th President]] of the [[Massachusetts Institute of Technology]]
* [[Dan Littman]], professor of Molecular Immunology at [[New York University]]
* [[Shantanu Narayen]], CEO of [[Adobe Inc.|Adobe]]
* [[Suzanne Nora Johnson]], former Vice Chairman of [[Goldman Sachs]]
* [[James Quincey]], CEO of [[The Coca-Cola Company]]
* [[James C. Smith (businessman)|James C. Smith]], former CEO of [[Thomson Reuters]]
* Cyrus Taraporevala, former President and CEO of [[State Street Global Advisors|State Street Global Advisor]]

==See also==
{{Portal|New York City|Companies}}
* [[Biotech and pharmaceutical companies in the New York metropolitan area]]
* [[Companies of the United States with untaxed profits]]
* [[Fire in the Blood (2013 film)|''Fire in the Blood'' (2013 film)]]
* [[List of pharmaceutical companies]]
* [[Pfizer Building]], its former New York City headquarters
* [[Pfizergate]]

==References==
{{Reflist}}

==External links==
{{Commons category-inline}}
* {{Official website}}
* {{OpenSecrets}}
{{Finance links
| name = Pfizer Inc.
| google = PFE
| reuters = PFE
| sec_cik = PFE
| yahoo = PFE
}}
{{coord|40.7553|-73.9996|format=dms|display=title}}
{{Pharmaceutical companies of the United States}}
{{Authority control}}

[[Category:Pfizer| ]]
[[Category:1849 establishments in New York (state)]]
[[Category:1940s initial public offerings]]
[[Category:American brands]]
[[Category:American companies established in 1849]]
[[Category:Biotechnology companies of the United States]]
[[Category:Chemical companies established in 1849]]
[[Category:Chemical companies of the United States]]
[[Category:Clinical trial organizations]]
[[Category:Companies based in Manhattan]]
[[Category:Companies listed on the New York Stock Exchange]]
[[Category:COVID-19 vaccine producers]]
[[Category:Former components of the Dow Jones Industrial Average]]
[[Category:Companies in the Dow Jones Global Titans 50]]
[[Category:Life sciences industry]]
[[Category:Multinational companies based in New York City]]
[[Category:Pharmaceutical companies established in 1849]]
[[Category:Pharmaceutical companies of the United States]]
[[Category:Publicly traded companies based in New York City]]
[[Category:Research and development in the United States]]
[[Category:Vaccine producers]]